

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) **EP 1 085 093 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:

**21.03.2001 Bulletin 2001/12**

(51) Int. Cl.<sup>7</sup>: **C12N 15/54, C12N 9/12,  
C07K 16/40, C12Q 1/68,  
C12Q 1/48, G01N 33/68**

(21) Application number: **00307866.4**

(22) Date of filing: **12.09.2000**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**

Designated Extension States:

**AL LT LV MK RO SI**

(72) Inventors:

- **Blumenberg, Miroslav**  
**New York, New York 10016 (US)**
- **Gazel, Alix M.**  
**11370, Leucate (FR)**

(30) Priority: **20.09.1999 US 155029 P**

(74) Representative:

**Simpson, Alison Elizabeth Fraser et al**  
**Urquhart-Dykes & Lord,**  
**30 Welbeck Street**  
**London W1G 8ER (GB)**

(71) Applicant: **NEW YORK UNIVERSITY**  
**New York, NY 10012 (US)**

(54) **Genes and polynucleotides associated with ultraviolet radiation-mediated skin damage and uses thereof**

(57) The invention relates to novel polynucleotides and their encoded gene products that are expressed in skin cells, particularly keratinocytes, and methods of using the same. Specifically, the present invention provides polynucleotides encoding several novel protein kinases that are c-Jun N-terminal kinase kinase kinases, i.e., MLK4, PAK4, PAK5 and YSK2. In addition, the invention provides methods of using the disclosed polynucleotides and their gene products in drug discovery, particularly in screening for drugs that can reduce ultraviolet light-induced damage of the skin, inflammation and psoriasis, and drugs that can enhance wound healing.

**BEST AVAILABLE COPY**

## Description

## 1. Field of the Invention

[0001] The invention provides novel polynucleotides, and their encoded gene products, that are expressed in skin cells, particularly keratinocytes, and methods of using the same. Specifically, the present invention relates to novel protein kinases that are c-Jun N-terminal kinase kinase kinases (JNKKKs). In addition, the invention provides methods of using the novel polynucleotides and their encoded products in drug discovery, particularly in screening for drugs that can reduce ultraviolet light-induced damage of the skin, inflammation and psoriasis, and drugs that can enhance wound heating.

## 2. Background of the Invention

[0002] Many extracellular signals, such as light, growth factors, cytokines and chemical or physical stresses, activate multi-tiered kinase cascades in the cytoplasm of cells. For example, a growth factor such as epidermal growth factor (EGF) will bind to its cognate receptor on the cell surface, thereby activating the intercellular protein ras, which is associated with the cytoplasmic portion of the cell surface receptor. Ras phosphorylates and thereby activates raf1, a mitogen-activated protein kinase kinase kinase (MAPKKK). Raf1 then induces (also by phosphorylation) the activation of mitogen-activated protein kinase kinases (MEKs), which in turn phosphorylate extracellular signal regulated kinases (ERKs). When phosphorylated, ERKs translocate to the nucleus where they phosphorylate and thus activate transcription factors such as stress activated protein kinase 1 (SAP1) and ternary complex factor Elk1. See, e.g., Fanger et al., 1997, Current Opin. Genet. Dev. 7:67-74.

[0003] Stress (such as heat and ultraviolet (UV) light) and cytokines (such as TNF- and IL-1) activate their own sets of kinase-kinase-kinases, termed JNKKKs. These, in turn, act on specific JNKs, which activate c-Jun-N terminal kinase (JNK) and p38. The last two kinases enter the nucleus, where they phosphorylate and activate transcription factors. See, e.g., Diene et al., 1997, PNAS 94:9687-92.

[0004] Most of the initial events in the cellular responses to different stresses have not been elucidated so far. However, it is clear that different extracellular signals activate different members of the JNKKK family. Thus, some JNKKKs are specifically responsive to TNF- $\alpha$ , others to osmotic shock, yet others to UV illumination. Diene et al., 1997, above; Raingeaud et al., 1995, J. Biol. Chem. 270:7420-6.

[0005] Skin cells such as keratinocytes are particularly susceptible to ultraviolet radiation damage. However, very little is known about how keratinocytes respond to ultraviolet radiation stress. Manipulation of keratinocyte responses to environmental stress could result in therapies for a wide variety of skin disorders, as well as cosmetic uses.

[0006] Therefore, there is a great need in the art to elucidate the components involved in keratinocyte signal transduction that can be used as targets for drug screening. Accordingly, this invention provides several novel JNKKKs expressed by keratinocytes and involved in the cellular response to ultraviolet radiation, and uses thereof.

## 3. Summary of the Invention

[0007] The present invention relates to polynucleotide molecules having nucleotide sequences that encode portions of several novel JNKKK gene products including an MLK4 kinase, a PAK4 kinase, a PAK5 kinase, and a YSK2 kinase, as well as the amino acid sequences encoded by these polynucleotide sequences. The present invention further relates to polynucleotide molecules having nucleotide sequences that encode a PAK5 kinase.

[0008] In one aspect, the invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human MLK4 gene product. In a preferred embodiment, the portion of the MLK4 gene product comprises the amino acid sequence of SEQ ID NO:2. In a non-limiting embodiment, the isolated polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:1.

[0009] The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:1. The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:2.

[0010] The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned MLK4-related polynucleotide molecules of the present invention. In a preferred embodiment, the substantial portion of the MLK4-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human MLK4 gene product or MLK4-related homologous polypeptide of the present invention. In a specific though non-limiting embodiment, the present invention provides a polynucleotide molecule consisting of a nucleotide sequence encoding a peptide fragment consisting of a sub-sequence of the amino acid sequence of SEQ ID NO:2.

**[0011]** In another aspect, the invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human PAK4 gene. In a preferred embodiment, the portion of the PAK4 gene product comprises the amino acid sequence of SEQ ID NO:4. In a non-limiting embodiment, the isolated polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:3.

**[0012]** The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:3. The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:4.

**[0013]** The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned PAK4-related polynucleotide molecules of the present invention. In a preferred embodiment, the substantial portion of the PAK4-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human PAK4 gene product or PAK4-related homologous polypeptide of the present invention. In a specific though non-limiting embodiment, the present invention provides a polynucleotide molecule consisting of a nucleotide sequence encoding a peptide fragment consisting of a sub-sequence of the amino acid sequence of SEQ ID NO:4.

**[0014]** In another aspect, the invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human PAK5 gene product. In a preferred embodiment, the portion of the PAK5 gene product comprises the amino acid sequence of SEQ ID NO:6. In a non-limiting embodiment, the isolated polynucleotide molecule encoding the amino acid sequence of SEQ ID NO:6 comprises the nucleotide sequence of SEQ ID NO:5.

**[0015]** In another aspect, invention provides an isolated polynucleotide molecule comprising a portion of the nucleotide sequence of the human PAK5 gene, which portion encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:8. In a non-limiting embodiment, the isolated polynucleotide molecule encoding the amino acid sequence of SEQ ID NO:8 comprises the nucleotide sequence of SEQ ID NO:7.

**[0016]** The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:5 or SEQ ID NO:7. The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:8.

**[0017]** In another aspect, the invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding the complete human PAK5 gene product having the amino acid sequence of SEQ ID NO:10. In a preferred embodiment, the polynucleotide molecule comprises the nucleotide sequence of SEQ ID NO:9 from nt 199 to nt 2244, which represents the ORF of the cDNA. In another non-limiting embodiment, the isolated polynucleotide molecule encoding the complete human PAK5 gene product comprises the nucleotide sequence of the ORF of SEQ ID NO:11 from nt 6125 to nt 17,433.

**[0018]** The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:9 or SEQ ID NO:11.

**[0019]** The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned PAK5-related polynucleotide molecules of the present invention. In a preferred embodiment, the substantial portion of the PAK5-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human PAK5 gene product or PAK5-related homologous polypeptide of the present invention.

**[0020]** In another aspect, the invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human YSK2 gene product. In a preferred embodiment, the portion of the YSK2 gene product comprises the amino acid sequence of SEQ ID NO:13. In a non-limiting embodiment, the isolated polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:12.

**[0021]** — The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:12. The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:13.

**[0022]** The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned YSK2-related polynucleotide molecules of the present invention. In a preferred embodiment, the substantial portion of the YSK2-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human YSK2 gene product or YSK2-related homologous polypeptide of the present invention. In a specific though non-limiting embodiment, the present invention provides a polynucleotide molecule consisting of a nucleotide sequence encoding a peptide fragment consisting of a sub-sequence of the amino acid sequence of SEQ ID NO:13.

**[0023]** The present invention further provides compositions and methods for cloning and expressing any of the polynucleotide molecules of the present invention, including cloning vectors and expression vectors comprising any of the polynucleotide molecules of the present invention, as well as transformed host cells and novel strains or cell lines

derived therefrom comprising any of the polynucleotide molecules, cloning vectors or expression vectors of the present invention. In a non-limiting embodiment, the present invention provides a recombinant expression vector comprising a polynucleotide molecule of the present invention in operative association with one or more regulatory elements for expression of the polynucleotide molecule.

5 **[0024]** Also provided by the present invention is a substantially purified or isolated polypeptide encoded by a polynucleotide molecule of the present invention. In a specific though non-limiting embodiment, the polypeptide is a portion of a human MLK4 gene product comprising the amino acid sequence of SEQ ID NO:2. In another specific though non-limiting embodiment, the polypeptide is a portion of a human PAK4 gene product comprising the amino acid sequence of SEQ ID NO:4. In another specific though non-limiting embodiment, the polypeptide is a portion of a human PAK5  
10 gene product, comprising the amino acid sequence of either SEQ ID NO:6 or SEQ ID NO:8, or is the entire human PAK5 gene product comprising the amino acid sequence of SEQ ID NO:10. In another specific though non-limiting embodiment, the polypeptide is a portion of a YSK2 gene product, comprising the amino acid sequence of SEQ ID NO:13.

**[0025]** The present invention also provides substantially purified or isolated polypeptides that are homologous to the portions of the human MLK4, PAK 4, PAK5 and YSK2 gene products of the present invention. The present invention also provides a substantially purified or isolated polypeptide that is homologous to the complete human PAK5 gene product of the present invention. The present invention further provides substantially purified or isolated peptide fragments of the MLK4, PAK4, and PAK5 gene products of the present invention, and substantially purified or isolated peptide fragments of the YSK2 gene product of the present invention that have the first six amino acids of SEQ ID NO:13.  
20 **[0026]** The present invention also provides a method of preparing a substantially purified or isolated portion of a human MLK4, PAK4, PAK5 or YSK2 gene product, or a substantially purified or isolated human PAK5 gene product, or a homologous peptide, or peptide fragment of the present invention, comprising culturing host cells transformed with a polynucleotide molecule or vector of the present invention under conditions conducive to the expression therefrom of the polypeptide or peptide fragment of the invention, and recovering the polypeptide or peptide fragment in substantially  
25 purified or isolated form from the cell culture.

**[0027]** Also provided are antibodies specific for the MLK4, PAK4, PAK5 or YSK2 gene product, homologous peptide, or peptide fragment of the present invention, and methods of detecting the MLK4, PAK4, PAK5 or YSK2 gene product, homologous peptide, or peptide fragment of the present invention in a sample. Still another aspect of the invention provides methods of identifying compounds that bind to the MLK4, PAK4, PAK5 or YSK2 gene product, homologous peptide, or peptide fragment of the present invention.  
30 **[0028]** The present invention also provides methods of detecting an MLK4, PAK4, PAK5 or YSK2-related polynucleotide in a sample, comprising contacting the sample with a compound that binds to and forms a complex with the particular polynucleotide for a period of time sufficient to form the complex, and detecting the complex, so that if a complex is detected, the MLK4, PAK4, PAK5 or YSK2-related polynucleotide, respectively, is detected. In a nonlimiting  
35 embodiment, the method comprises contacting the sample under stringent hybridization conditions with nucleic acid primers that anneal to the particular polynucleotide under such hybridization conditions, and amplifying the annealed polynucleotides, so that if a particular polynucleotide is amplified, the MLK4, PAK4, PAK5 or YSK2-related polynucleotide, respectively, is detected.

**[0029]** The invention further provides a method of screening for compounds that affect the cellular levels of a JNKKK gene product, comprising: (a) applying a test compound to a test sample; (b) determining the cellular levels of at least one gene product in the test sample, wherein the gene product is from a gene comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11 and 12; and (c) comparing the levels of the gene product in the test sample with that in a reference sample; wherein a specific change in the cellular levels of the gene product in the test sample as compared to the reference sample indicates that the test compound affects the cellular levels of gene product from a JNKKK gene. In a preferred embodiment, the method further comprises the step  
45 of applying a stress event to the test sample and determining the effect of the test compound on the response of the test sample to the stress event.

**[0030]** The invention further provides a method of screening for compounds that affect the expression of a gene that encodes a JNKKK gene product, comprising: (a) applying a test compound to a test sample; (b) determining the expression level of at least one gene in cells of the test sample, wherein the gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11 and 12; and (c) comparing the expression level of the gene in the test sample with that in a reference sample; wherein a specific change in the expression of the gene in the test sample as compared to the reference sample indicates that the test compound affects the expression of the gene. In a preferred embodiment, the method further comprises the step of applying a stress event to the test sample  
50 and determining the effect of the test compound on the gene expression response of the test sample to the stress event.

**[0031]** Still another aspect of the invention provides a method of screening for compounds that affect the activity of a JNKKK gene product, the method comprising: (a) applying a test compound to a test sample; and (b) determining the activity of a JNKKK gene product in the test sample versus a reference sample, wherein the JNKKK gene product com-

prises an amino acid sequence selected from the group consisting of: SEQ ID NOS: 2, 4, 6, 8, 10 and 13; wherein a test compound that alters the JNKKK gene product activity in the test sample as compared to the reference sample is identified as a compound that affects the activity of the JNKKK gene product. In a preferred embodiment, the method further comprises the step of applying a stress event to the test sample and determining the effect of the test compound on the response of the test sample to the stress event.

#### 4. Brief Description of the Figures

[0032]

Figure 1 is a schematic diagram illustrating the structure of the PAK5 gene.

Figure 2 is a Northern Blot illustrating the tissue-specific expression of MLK4, PAK4 and PAK5 genes. Messenger RNA was isolated from heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas, run on a denaturing gel in the indicated lanes, and blotted to a membrane. The same blot was sequentially hybridized (after stripping between hybridizations) to labeled 150 base pair probes specific for MLK4, PAK4 and PAK5.

Figure 3 shows the induction of YSK2 and PAK5 genes in response to ultraviolet radiation. Figure 3A is a Northern blot of mRNA from keratinocytes untreated (control) or treated (control) with UV-C radiation for 5 days. The blot was hybridized to a 150 base pair probe specific for the YSK2 gene. Figure 3B shows a differential display experiment designed to examine any change in expression levels of the PAK4 and PAK5 genes in response to UV-A light. Keratinocytes were exposed to UV-A light for 0, 6 or 24 hours, harvested and mRNA analyzed. Bands corresponding the PAK4 and PAK5 message are indicated.

#### 5. Detailed Description of the Invention

[0033] The present invention relates to identification and characterization of polynucleotide molecules expressed in skin keratinocytes, which polynucleotide molecules encode JNKKK polypeptides. Because the kinase domains of JNKKKs are conserved in sequence, primers can be designed for reverse transcription-polymerase chain reaction (RT-PCR) detection of virtually all the JNKKKs expressed by a cell or cell type. In one embodiment, the primer pair 5'-ATGCA(CA)CANGA(CT)AT(ACT)AA(AG)-3' (SEQ ID NO:14) (forward) and 5'-GCNAC(CT)TCNGGNGCCATCCA-3' (SEQ ID NO:15) (reverse) can be used to detect novel JNKKKs. The product of using the primer pair is a common 150 bp segment. As discussed below in the Example sections, a primer pair was used to screen human epidermal keratinocyte mRNA, and polynucleotides encoding several novel JNKKKs were discovered. In addition, the present invention relates to the discovery that the JNKKKs encoded by these polynucleotides are involved in the cellular response to stress such as ultraviolet (UV) light. By way of example, the invention is described in the sections below for an isolated polynucleotide molecule comprising the nucleotide sequence of a portion of the MLK4 open reading frame (ORF) (SEQ ID NO:1); for an isolated polynucleotide molecule comprising the nucleotide sequence of a portion of the PAK4 ORF (SEQ ID NO:3); for an isolated polynucleotide molecule comprising the nucleotide sequence of a portion of the PAK5 ORF (SEQ ID NO:5); for another isolated polynucleotide molecule comprising the nucleotide sequence of a portion of the PAK5 gene (SEQ ID NO:7); for an isolated polynucleotide molecule comprising the nucleotide sequence of the cDNA encoding the PAK5 gene product (SEQ ID NO:9, ORF from nt 199-2244); for an isolated polynucleotide molecule comprising the nucleotide sequence of the PAK5 gene (SEQ ID NO:11, ORF from nt 6125-17433); and for an isolated polynucleotide molecule comprising the nucleotide sequence of a portion of the YSK2 ORF (SEQ ID NO:12).

##### 5.1. Polynucleotide Molecules

[0034] As used herein, the terms "polynucleotide molecule," "polynucleotide sequence," "coding sequence" "open-reading frame (ORF)", and the like, are intended to refer to both DNA and RNA molecules, which can either be single-stranded or double-stranded. A coding sequence or ORF can include but is not limited to prokaryotic sequences, cDNA sequences, genomic DNA sequences, and chemically synthesized DNA and RNA sequences. A "gene product" is intended to refer to a product encoded by a gene, including the transcribed RNA message (including exons and introns), the spliced messenger RNA (mRNA), and the translated protein product encoded by the respective mRNA.

[0035] Production and manipulation of the polynucleotide molecules and oligonucleotide molecules disclosed herein are within the skill in the art and can be carried out according to recombinant techniques described, among other places, in Maniatis et al. 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Ausubel et al., 1989, Greene Publishing Associates & Wiley Interscience, NY; Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Innis et al. (eds), 1995, PCR Strategies, Academic Press, Inc., San Diego; and Erlich (ed), 1992, PCR Technology, Oxford University Press, New York, all of which are incorporated herein by reference.

### 5.1.1. MLK4-related Polynucleotide Molecules

**[0036]** The present invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human MLK4-related gene product. In a preferred embodiment, the portion of the MLK4 gene product comprises the amino acid sequence of SEQ ID NO:2. In a non-limiting embodiment, the isolated polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:1.

**[0037]** The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:1. The term "homologous" when used in this respect means a polynucleotide molecule comprising a nucleotide sequence: (a) that encodes the same polypeptide as encoded by SEQ ID NO:1, but that includes one or more silent changes to the nucleotide sequence according to the degeneracy of the genetic code (i.e., a degenerate variant); or (b) that has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% nucleotide sequence identity to the nucleotide sequence of SEQ ID NO:1, as determined by any standard nucleotide sequence identity algorithm such as BLASTN (GENBANK), and which hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2 under moderately stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO<sub>4</sub>, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.2XSSC/0.1% SDS at 42°C (see Ausubel et al. (eds.), 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, at p. 2.10.3), and is useful in practicing the invention. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2 under highly stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO<sub>4</sub>, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1 x SSC/0.1% SDS at 68°C (Ausubel et al., 1989, above), and is useful in practicing the invention. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule consisting of the nucleotide sequence of SEQ ID NO:1, and is useful in practicing the invention.

**[0038]** As used herein, an MLK4-related polynucleotide molecule is "useful in practicing the invention" where the polynucleotide molecule: (i) encodes a peptide that can be used to generate antibodies that immunospecifically recognize the MLK4 gene product from a eukaryotic cell; or (ii) can detect the presence of the MLK4 transcript in a test sample; or (iii) can enable a method for altering the regulation or expression of the endogenous MLK4 gene (such as by gene activation or inactivation techniques, e.g., insertion of a transcriptional activator sequence into an intron, or deletion of one or more exons); or (iv) can be used to amplify a polynucleotide molecule comprising the nucleotide sequence of the MLK4 ORF in a eukaryotic cell using standard amplification techniques such as PCR. Such homologous polynucleotide molecules can include naturally occurring MLK4 genes present in eukaryotic species other than humans (and particularly in mammalian species, such as, for example, mouse, cow, sheep, guinea pig and rat), or in other human isolates, as well as mutated MLK4 alleles, whether naturally occurring, chemically synthesized, or genetically engineered.

**[0039]** The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:2. As used herein to refer to polypeptides having amino acid sequences that are homologous to the amino acid sequence of a portion of an MLK4 gene product from a human, the term "homologous" means a polypeptide comprising the amino acid sequence of SEQ ID NO:2, but in which one or more amino acid residues thereof has been conservatively substituted with a different amino acid residue, wherein the resulting amino acid sequence has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% sequence identity to SEQ ID NO:2 wherein amino acid sequence identity is determined by any standard amino acid sequence identity algorithm, such as, e.g., BLASTP (GENBANK), where the resulting polypeptide is useful in practicing the invention. Conservative amino acid substitutions are well known in the art. Rules for making such substitutions include those described by Dayhof, M.D., 1978, Nat. Biomed. Res. Found., Washington, D.C., Vol. 5, Sup. 3, among others. More specifically, conservative amino acid substitutions are those that generally take place within a family of amino acids that are related in the acidity, or polarity of their side chains. Genetically encoded amino acids are generally divided into four groups: (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine, histidine; (3) non-polar = alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar = glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. Phenylalanine, tryptophan and tyrosine are also jointly classified as aromatic amino acids. One or more replacements within any particular group, e.g., of a leucine with an isoleucine or valine, or of an aspartate with a glutamate, or of a threonine with a serine, or of any other amino acid residue with a structurally related amino acid residue, e.g., an amino acid residue with similar acidity, or polarity or with similarity in a combination thereof, will generally have an insignificant effect on the function of the polypeptide.

**[0040]** As used herein, an MLK4-related polypeptide is "useful in practicing the invention" where the polypeptide can be used to raise antibodies against an MLK4 gene product from a eukaryotic, preferably mammalian, and most

preferably human cell or tissue, or to screen for compounds that modulate MLK4 activity or production in such a cell or tissue.

[0041] The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned MLK4-related polynucleotide molecules of the present invention. As used herein, a "substantial portion" of an MLK4-related polynucleotide molecule means a polynucleotide molecule consisting of less than the full length of the nucleotide sequence of SEQ ID NO:1 or homologous polynucleotide molecule thereof, but comprising at least about 20%, and more preferably at least about 30%, of the length of said nucleotide sequence, and that is useful in practicing the invention, as usefulness is defined above for MLK4-related polynucleotide molecules. In a non-limiting embodiment, the substantial portion of the MLK4-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human MLK4 gene product of the present invention. A "peptide fragment" of an MLK4-related polypeptide refers to a polypeptide consisting of a subsequence of SEQ ID NO:2, which sub-sequence is useful in practicing the invention, as usefulness is defined above for MLK4-related polypeptides. As used herein, a "peptide fragment" is preferably at least about 15 amino acid residues, and more preferably at least about 30 amino acid residues in length.

[0042] The MLK4-related polynucleotide molecules disclosed herein can be used to express a portion of the human MLK4 gene product, to detect expression of an MLK4 gene product in a cell type or tissue, to prepare novel cell lines in which the MLK4 gene has been mutated (for example, altered or removed by homologous recombination), to create and express a dominant-negative MLK4, e.g., by mutating the ATP binding site, using well known techniques (see, e.g., Abo et al., below), and to identify MLK4 homolog genes in eukaryotic species other than humans, and particularly in other mammalian species, using known techniques. Thus, the present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding an MLK4 homolog gene product. As used herein, an "MLK4 homolog gene product" is defined as a gene product encoded by an MLK4 homolog gene which, in turn, is defined as a gene from a different eukaryotic species other than human and which is recognized by those of skill in the art as a homolog of the human MLK4 gene based on a degree of sequence identity at the amino acid level of greater than about 70%.

[0043] Methods for identifying polynucleotide clones containing MLK4 homolog genes are known in the art. For example, a polynucleotide molecule comprising a portion of the human MLK4 ORF can be detectably labeled and used to screen a genomic library constructed from DNA derived from the organism of interest. The stringency of the hybridization conditions can be selected based on the relationship of the reference organism to the organism of interest. Requirements for different stringency conditions are well known to those of skill in the art, and such conditions will vary predictably depending on the specific organisms from which the library and the labeled sequences are derived. Genomic DNA libraries can be screened for MLK4 homolog gene coding sequences using the techniques set forth, among other places, in Benton and Davis, 1977, Science 196:180, for bacteriophage libraries, and in Grunstein and Hogness, 1975, Proc. Natl. Acad. Sci. USA, 72:3961-3965, for plasmid libraries, which publications are incorporated herein by reference. Polynucleotide molecules having nucleotide sequences known to include a portion of the MLK4 ORF, as shown in SEQ ID NO:1, or oligonucleotide molecules representing portions thereof, can be used as probes in these screening experiments. Alternatively, oligonucleotide probes can be synthesized that correspond to nucleotide sequences deduced from the amino acid sequence of the purified MLK4 gene product.

[0044] Clones identified as containing MLK4 homolog gene coding sequences can be tested for appropriate biological function. For example, the clones can be subjected to sequence analysis in order to identify a suitable reading frame, as well as initiation and termination signals. The cloned DNA sequence can then be inserted into an appropriate expression vector which is then transformed into cells (such as human cells) that have been rendered MLK4 null to test for complementation. Transformed host cells can then be analyzed for MLK4 signal transduction.

#### 5.1.2. PAK4-related Polynucleotide Molecules

[0045] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human PAK4 gene product. In a preferred embodiment, the portion of the PAK4 gene product comprises the amino acid sequence of SEQ ID NO:4. In a non-limiting embodiment, the isolated polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:3.

[0046] The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:3. The term "homologous" when used in this respect means a polynucleotide molecule comprising a nucleotide sequence: (a) that encodes the same polypeptide as encoded by SEQ ID NO:3, but that includes one or more silent changes to the nucleotide sequence according to the degeneracy of the genetic code; or (b) that has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% nucleotide sequence identity to the nucleotide sequence of SEQ ID NO:3, as determined by any standard nucleotide sequence identity algorithm such as BLASTN (GENBANK) and hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid

sequence of SEQ ID NO:4 under moderately stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO<sub>4</sub>, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel et al., 1989, above), and is useful in practicing the invention. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:4 under highly stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO<sub>4</sub>, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1 % SDS at 68°C (Ausubel et al., 1989, above), and is useful in practicing the invention. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:3, and is useful in practicing the invention.

**[0047]** As used herein, a PAK4-related polynucleotide molecule is "useful in practicing the invention" where the polynucleotide molecule: (i) encodes a peptide that can be used to generate antibodies that immunospecifically recognize the PAK4 gene product from a eukaryotic cell; or (ii) can detect the presence of the PAK4 transcript in a test sample; or (iii) can enable a method for altering the regulation or expression of the endogenous PAK4 gene (such as by gene activation or inactivation techniques, e.g., insertion of a transcriptional activator sequence into an intron, or deletion of one or more exons); or (iv) can be used to amplify a polynucleotide molecule comprising the nucleotide sequence of the PAK4 ORF in a eukaryotic cell using standard amplification techniques such as PCR. Such homologous polynucleotide molecules can include naturally occurring PAK4 genes present in eukaryotic species other than humans (and particularly in mammalian species, such as, for example, mouse, cow, sheep, guinea pig and rat), or in other human isolates, as well as mutated PAK4 alleles, whether naturally occurring, chemically synthesized, or genetically engineered.

**[0048]** The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:4. As used herein to refer to polypeptides having amino acid sequences that are homologous to the amino acid sequence of a PAK4 gene product from a human cell, the term "homologous" means a polypeptide comprising the amino acid sequence of SEQ ID NO:4, but in which one or more amino acid residues thereof has been conservatively substituted with a different amino acid residue, as conservative amino acid substitutions are defined above, wherein the resulting amino acid sequence has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% sequence identity to SEQ ID NO:4, as determined, e.g., using the BLASTP algorithm (GENBANK), where the resulting polypeptide is useful in practicing the invention.

**[0049]** As used herein, a PAK4-related polypeptide is "useful in practicing the invention" where the polypeptide can be used to raise antibodies against a PAK4 gene product from a eukaryotic, preferably mammalian, and most preferably human, cell or tissue, or to screen for compounds that modulate PAK4 activity or production in such a cell or tissue.

**[0050]** The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned PAK4-related polynucleotide molecules of the present invention. As used herein, a "substantial portion" of a PAK4-related polynucleotide molecule means a polynucleotide molecule consisting of less than the full length of SEQ ID NO:3 or homologous polynucleotide molecule thereof, but comprising at least about 20%, and more preferably at least about 30%, of the length of said nucleotide sequence, and that is useful in practicing the invention, as usefulness is defined above for PAK4-related polynucleotide molecules. In a non-limiting embodiment, the substantial portion of the PAK4-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human PAK4 gene product of the present invention. A "peptide fragment" of a PAK4-related polypeptide refers to a polypeptide consisting of a sub-sequence of SEQ ID NO:4, which sub-sequence is useful in practicing the invention, as usefulness is defined above for PAK4-related polypeptides. Peptide fragments of the invention are preferably at least about 15 amino acid residues, and more preferably at least about 30 amino acid residues in length.

**[0051]** The PAK4-related polynucleotide molecules disclosed herein can be used to express a portion of the human PAK4 gene product, to detect expression of a PAK4 gene product in a cell type or tissue, to prepare novel cell lines in which the PAK4 gene has been mutated (for example, altered or removed by homologous recombination), to create and express a dominant-negative PAK4, e.g., by mutating the ATP binding site, using well known techniques (see, e.g., Abo et al., below), and to identify PAK4 homolog genes in eukaryotic species other than humans, and particularly in other mammalian species, using known techniques. Thus, the present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a PAK4 homolog gene product. As used herein, a "PAK4 homolog gene product" is defined as a gene product encoded by a PAK4 homolog gene which, in turn, is defined as a gene from a different eukaryotic species other than human and which is recognized by those of skill in the art as a homolog of the human PAK4 gene based on a degree of sequence identity at the amino acid level of greater than about 70%. Methods for identifying polynucleotide clones containing PAK4 homolog genes are known in the art as described above.



**5.1.3. PAK5-related Polynucleotide Molecules**

**[0052]** The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human PAK5 gene product. In a preferred embodiment, the portion of the PAK5 gene product comprises the amino acid sequence of SEQ ID NO:6. In a non-limiting embodiment, the isolated polynucleotide molecule encoding the amino acid sequence of SEQ ID NO:6 comprises the nucleotide sequence of SEQ ID NO:5. In another preferred embodiment, the portion of the PAK5 gene product comprises the amino acid sequence of SEQ ID NO:8. In a non-limiting embodiment, the isolated polynucleotide molecule encoding the amino acid sequence of SEQ ID NO:8 comprises the nucleotide sequence of SEQ ID NO:7. Still another non-limiting embodiment of the invention is the sequence of any one of the exons of the PAK5 genomic DNA (see SEQ ID NO:7). A further non-limiting embodiment of the invention is the sequence of any one of the introns of the PAK5 genomic DNA.

**[0053]** The present invention further provides an isolated polynucleotide molecule comprising the cDNA nucleotide sequence of SEQ ID NO:9 (ORF from nt 199-2244) encoding a complete human PAK5 gene product. The present invention further provides an isolated polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:11 (ORF from nt 6125-17433), which represents the human PAK5 gene.

**[0054]** The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising a nucleotide sequence encoding a portion of a PAK5 gene product of the present invention. The term "homologous" when used in this respect means a polynucleotide molecule comprising a nucleotide sequence: (a) that encodes the same polypeptide as encoded by SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 or SEQ ID NO:11, but that includes one or more silent changes to the nucleotide sequence according to the degeneracy of the genetic code; or (b) that has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% nucleotide sequence identity to the nucleotide sequence of SEQ ID NO:5 or SEQ ID NO:7, or to the ORF of SEQ ID NO:9 or SEQ ID NO:11, as determined by any standard nucleotide sequence identity algorithm such as BLASTN (GENBANK), and hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:6, SEQ ID NO:8, or SEQ ID NO:10 under moderately stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO<sub>4</sub>, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel et al., 1989, above), and is useful in practicing the invention. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:6, SEQ ID NO:8, or SEQ ID NO:10 under highly stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO<sub>4</sub>, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1 % SDS at 68°C (Ausubel et al., 1989, above), and is useful in practicing the invention. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule consisting of the nucleotide sequence of SEQ ID NO:5 or SEQ ID NO:7, or the ORF of SEQ ID NO:9 or SEQ ID NO:11, and is useful in practicing the invention.

**[0055]** As used herein, a PAK5-related polynucleotide molecule is "useful in practicing the invention" where the polynucleotide molecule: (i) encodes a peptide that can be used to generate antibodies that immunospecifically recognize the PAK5 gene product from a eukaryotic cell; or (ii) can detect the presence of the PAK5 transcript in a test sample; or (iii) can enable a method for altering the regulation or expression of the endogenous PAK5 gene (such as by gene activation or inactivation techniques, e.g., insertion of a transcriptional activator sequence into an intron, or deletion of one or more exons); or (iv) can be used to amplify a polynucleotide molecule comprising the nucleotide sequence of the PAK5 ORF in a eukaryotic cell using standard amplification techniques such as PCR. Such homologous polynucleotide molecules can include naturally occurring PAK5 genes present in eukaryotic species other than humans (and particularly in mammalian species, such as, for example, mouse, cow, sheep, guinea pig and rat), or in other human isolates, as well as mutated PAK5 alleles, whether naturally occurring, chemically synthesized, or genetically engineered.

**[0056]** The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10. As used herein to refer to polypeptides having amino acid sequences that are homologous to the amino acid sequence of a PAK5 gene product from a human cell, the term "homologous" means a polypeptide comprising the amino acid sequence of SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10, but in which one or more amino acid residues thereof has been conservatively substituted with a different amino acid residue, as conservative amino acid substitutions are defined above, wherein the resulting amino acid sequence has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% sequence identity to SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10, as determined, e.g., using the BLASTP algorithm (GENBANK), and where the resulting polypeptide is useful in practicing the invention.

**[0057]** As used herein, a PAK5-related polypeptide is "useful in practicing the invention" where the polypeptide can be used to raise antibodies against a PAK5 gene product from a eukaryotic, preferably mammalian, and most preferably

human, cell or tissue, or to screen for compounds that modulate PAK5 activity or production in such a cell.

**[0058]** The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned PAK5-related polynucleotide molecules of the present invention. As used herein, a "substantial portion" of a PAK5-related polynucleotide molecule means a polynucleotide molecule consisting of less than the full length of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 (from nt 199-2244) or SEQ ID NO:11 (from nt 6125-17433) or homologous polynucleotide molecule thereof, but comprising at least about 20%, and more preferably at least about 30%, the length of said nucleotide sequence, and that is useful in practicing the invention, as usefulness is defined above for PAK5-related polynucleotide molecules. In a non-limiting embodiment, the substantial portion of the PAK5-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human PAK5 gene product of the present invention. A "peptide fragment" of a PAK5-related polypeptide refers to a polypeptide consisting of a sub-sequence of SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10, which sub-sequence is useful in practicing the invention, as usefulness is defined above for PAK5-related polypeptides. Peptide fragments of the invention are preferably at least about 15 amino acid residues, and more preferably at least about 30 amino acid residues in length.

**[0059]** The PAK5-related polynucleotide molecules disclosed herein can be used to express a portion of the PAK5 gene product, to detect expression of a PAK5 gene in a cell or tissue, to prepare novel cell lines in which the PAK5 gene has been mutated (for example, altered or removed by homologous recombination), to create and express a dominant-negative PAK5 by mutating the ATP binding site using well known techniques (see, e.g., Abo et al., below), and to identify PAK5 homolog genes in other eukaryotic species or cell types using standard techniques. Thus, the present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a PAK5 homolog gene product. As used herein, a "PAK5 homolog gene product" is defined as a gene product encoded by a PAK5 homolog gene which, in turn, is defined as a gene from a eukaryotic species other than human, and which is recognized by those of skill in the art as a homolog of the human PAK5 gene based on a degree of sequence identity at the amino acid level of greater than about 80%. Methods for identifying polynucleotide clones containing PAK5 homolog genes are known in the art, as described above.

#### 5.1.4. YSK2-related Polynucleotide Molecules

**[0060]** The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a YSK2 gene product from a human cell. In a preferred embodiment, the YSK2 gene product comprises the amino acid sequence of SEQ ID NO:13. In a non-limiting embodiment, the isolated polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:12.

**[0061]** The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising a nucleotide sequence encoding a portion of the YSK2 gene product of the present invention. The term "homologous" when used in this respect means a polynucleotide molecule comprising a nucleotide sequence: (a) that encodes the same polypeptide as encoded by SEQ ID NO:12, but that includes one or more silent changes to the nucleotide sequence according to the degeneracy of the genetic code; or (b) that has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% nucleotide sequence identity to the nucleotide sequence of SEQ ID NO:12, as determined by any standard nucleotide sequence identity algorithm such as BLASTN (GENBANK), and hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:13 under moderately stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO<sub>4</sub>, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel et al., 1989, above), and encodes at least the first 6 amino acid residues of SEQ ID NO:13 and is useful in practicing the invention. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:13 under highly stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO<sub>4</sub>, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1 % SDS at 68°C (Ausubel et al., 1989, above), and encodes at least the first 6 amino acid residues of SEQ ID NO:13, and is useful in practicing the invention. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:12, and encodes at least the first 6 amino acid residues of SEQ ID NO:13, and is useful in practicing the invention.

**[0062]** As used herein, a YSK2-related polynucleotide molecule is "useful in practicing the invention" where the polynucleotide molecule: (i) encodes a peptide that can be used to generate antibodies that immunospecifically recognize the YSK2 gene product from a eukaryotic cell; or (ii) can detect the presence of the YSK2 transcript in a test sample; or (iii) can enable a method for altering the regulation or expression of the endogenous YSK2 gene (such as by gene activation or inactivation techniques, e.g., insertion of a transcriptional activator sequence into an intron, or deletion of one or more exons); or (iv) can be used to amplify a polynucleotide molecule comprising the nucleotide

sequence of the YSK2 ORF in a eukaryotic cell using standard amplification techniques such as PCR. Such homologous polynucleotide molecules can include naturally occurring YSK2 genes present in eukaryotic species other than humans (and particularly in mammalian species, such as, for example, mouse, cow, sheep, guinea pig and rat), or in other human isolates, as well as mutated YSK2 alleles, whether naturally occurring, chemically synthesized, or genetically engineered.

[0063] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:13. As used herein to refer to polypeptides having amino acid sequences that are homologous to the amino acid sequence of a YSK2 gene product from a human cell, the term "homologous" means a polypeptide comprising the amino acid sequence of SEQ ID NO:13, but in which one or more amino acid residues thereof has been conservatively substituted with a different amino acid residue, as conservative amino acid substitutions are defined above, wherein the resulting amino acid sequence has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% sequence identity to SEQ ID NO:13, as determined, e.g., using the BLASTP algorithm (GENBANK), and which encodes at least the first 6 amino acid residues of SEQ ID NO:13 and where the resulting polypeptide is useful in practicing the invention.

[0064] As used herein, a YSK2-related polypeptide is "useful in practicing the invention" where the polypeptide can be used to raise antibodies against a YSK2 gene product from a eukaryotic, preferably mammalian, and most preferably human, cell or tissue, or to screen for compounds that modulate YSK2 activity or production in such a cell or tissue.

[0065] The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned YSK2-related polynucleotide molecules of the present invention. As used herein, a "substantial portion" of a YSK2-related polynucleotide molecule means a polynucleotide molecule consisting of less than the full length of SEQ ID NO:12 or homologous polynucleotide molecule thereof, but comprising at least about 20%, and more preferably at least about 30%, the length of said nucleotide sequence, and encoding at least the first 6 amino acid residues of SEQ ID NO:13 and that is useful in practicing the invention, as usefulness is defined above for YSK2-related polynucleotide molecules. In a non-limiting embodiment, the substantial portion of the YSK2-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a YSK2 gene product of the present invention. A "peptide fragment" of a YSK2-related polypeptide refers to a polypeptide consisting of a sub-sequence of the amino acid sequence of SEQ ID NO:13, yet contains the sequence of residues 1 to 6 of SEQ ID NO:13, and which sub-sequence is useful in practicing the invention, as usefulness is defined above for YSK2-related polypeptides. Peptide fragments of the invention are preferably at least about 15 amino acid residues, and more preferably at least about 30 amino acid residues in length.

[0066] The YSK2-related polynucleotide molecules disclosed herein can be used to express a portion of the human YSK2 gene product, to detect expression of a YSK2 gene product in a cell type or tissue, to prepare novel cell lines in which the YSK2 gene has been mutated (for example, altered or removed by homologous recombination), to create and express a dominant-negative YSK2 by mutating the ATP binding site using well known techniques (see, e.g., Abo et al., below), and to identify YSK-2 homolog genes in other eukaryotic species or cell types, as described above. As used herein, a "YSK2 homolog gene product" is defined as a gene product encoded by a YSK2 homolog gene which, in turn, is defined as a gene from a eukaryotic species other than human, and which is recognized by those of skill in the art as a homolog of the human YSK2 gene based on a degree of sequence identity at the amino acid level of greater than about 80%. Methods for identifying polynucleotide clones containing YSK2 homolog genes are known in the art, as described above.

## 5.2. Oligonucleotide Molecules

[0067] The present invention further provides oligonucleotide molecules that hybridize to any of the aforementioned polynucleotide molecules of the present invention, or that hybridize to a polynucleotide molecule having a nucleotide sequence that is the complement of any of the aforementioned polynucleotide molecules of the present invention. Such oligonucleotide molecules are preferably at least about 10 nucleotides in length, and more preferably at least about 20 nucleotides in length, and can hybridize to one or more of the aforementioned polynucleotide molecules under moderately or highly stringent conditions. For shorter oligonucleotide molecules, an example of highly stringent conditions includes washing in 6xSSC/0.5% sodium pyrophosphate at about 37°C for ~14-base oligos, at about 48°C for ~17-base oligos, at about 55°C for ~20-base oligos, and at about 60°C for ~23-base oligos. For longer oligonucleotide molecules (i.e., greater than about 100 nts), examples of moderately and highly stringent conditions are described in Section 5.1.1 above for homologous polynucleotide molecules. Hybridization conditions can be appropriately adjusted as known in the art, depending upon the particular oligonucleotide molecules utilized.

[0068] In a preferred embodiment, an oligonucleotide molecule of the present invention hybridizes under highly stringent conditions to a polynucleotide molecule having a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11 or 12, or to a polynucleotide molecule having a nucleotide sequence that is the comple-

ment of a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11 or 12.

[0069] The oligonucleotide molecules of the present invention are useful for a variety of purposes, including as primers in amplifying a MLK4, PAK4, PAK5 or YSK2 gene product-encoding polynucleotide molecule, or as anti-sense molecules useful in regulating expression of JNKKK genes and gene products. Amplification can be carried out using suitably designed oligonucleotide molecules in conjunction with standard techniques, such as the polymerase chain reaction (PCR), although other amplification techniques known in the art, e.g., the ligase chain reaction, can also be used. For example, for PCR, a mixture comprising suitably designed primers, a template comprising the nucleotide sequence to be amplified, and appropriate PCR enzymes and buffers, is prepared and processed according to standard protocols to amplify a specific MLK4-, PAK4-, PAK5-, or YSK2-related polynucleotide sequence of the template.

### 5.3. Recombinant Expression Systems

#### 5.3.1. Expression Vectors

[0070] The present invention further provides recombinant cloning vectors and recombinant expression vectors comprising a polynucleotide molecule of the present invention, which vectors are useful in cloning or expressing said polynucleotide molecules, including polynucleotide molecules comprising portions of the MLK4, PAK4, PAK5 or YSK2 ORFs, or the entire PAK5 ORF, of the present invention.

[0071] The following description is intended to apply to all of the aforementioned polynucleotide molecules and polypeptides of the present invention, including polynucleotide molecules comprising portions of the MLK4, PAK4, PAK5 or YSK2 ORFs, the entire PAK5 ORF, and their gene products, and all homologous polynucleotide molecules, homologous polypeptides, substantial portions of such polynucleotide molecules, and peptide fragments of such gene products and polypeptides, as defined above, unless otherwise indicated.

[0072] Recombinant vectors of the present invention, particularly expression vectors, are preferably constructed so that the coding sequence for the polynucleotide molecule of the present invention is in operative association with one or more regulatory elements necessary for transcription and translation of the coding sequence to produce a polypeptide. As used herein, the term "regulatory element" includes but is not limited to nucleotide sequences of inducible and noninducible promoters, enhancers, operators and other elements known in the art that serve to drive and/or regulate expression of polynucleotide coding sequences. Also, as used herein, the coding sequence is in "operative association" with one or more regulatory elements where the regulatory elements effectively regulate and allow for the transcription of the coding sequence or the translation of its mRNA, or both.

[0073] Typical plasmid vectors that can be engineered to contain a polynucleotide molecule of the present invention include pCR-Blunt, pCR2.1 (Invitrogen), and pGEM3Zf (Promega), among many others. Additionally, vectors particularly designed for expression in eukaryotic cells, such as mammalian cells, are commercially available from Invitrogen (San Diego, CA) and Promega.

[0074] The regulatory elements of these vectors can vary in their strength and specificities. Depending on the host/vector system utilized, any of a number of suitable transcription and translation elements can be used. Non-limiting examples of transcriptional regulatory regions or promoters for bacteria include the  $\beta$ -gal promoter, the T7 promoter, the TAC promoter, lambda left and right promoters, trp and lac promoters, and the trp-lac fusion promoters. Non-limiting examples of transcriptional regulatory regions or promoters for eukaryotic cells include viral regulatory regions such as, for example, the SV40 early promoter region, the herpes thymidine kinase promoter, the cytomegalovirus (CMV) promoter, and the mouse mammary tumor virus control region, tissue specific or inducible promoters from endogenous eukaryotic genes such as, for example, the albumin promoter, myosin light chain-2 promoter, the insulin promoter, the metallothionein promoter, and fungal promoters such as, for example, the gal 4 promoter, the alcohol dehydrogenase promoter, the phosphoglycerol kinase promoter, and the mating factor promoters, to name just a few.

[0075] Methods are well-known in the art for constructing recombinant vectors containing particular coding sequences in operative association with appropriate regulatory elements, and any of these can be used to practice the present invention. These methods include in vitro recombinant techniques, synthetic techniques, and in vivo genetic recombination. See, e.g., the techniques described in Maniatis et al., 1989, above; Ausubel et al., 1989, above; Sambrook et al., 1989, above; Innis et al., 1995, above; and Erlich, 1992, above.

[0076] Fusion protein expression vectors can be used to express an MLK4, PAK4, PAK5 or YSK2 gene product-fusion protein. The purified fusion protein can be used to raise antisera against the MLK4, PAK4, PAK5 or YSK2 gene product, to study the biochemical properties of the MLK4, PAK4, PAK5 or YSK2 gene product, to engineer the MLK4, PAK4, PAK5 or YSK2 fusion proteins with different biochemical activities, or to aid in the identification or purification of the expressed MLK4, PAK4, PAK5 or YSK2 gene product in recombinant expression systems. Possible fusion protein expression vectors include but are not limited to vectors incorporating sequences that encode  $\beta$ -galactosidase and trpE fusions, maltose binding protein fusions, glutathione-S-transferase fusions and polyhistidine fusions (carrier regions).

[0077] MLK4, PAK4, PAK5 or YSK2 fusion proteins can be engineered to comprise a region useful for purification.

For example, MLK4-, PAK4-, PAK5- and YSK2-maltose-binding protein fusions can be purified using amylose resin; MLK4-, PAK4-, PAK5- and YSK2-glutathione-S-transferase fusion proteins can be purified using glutathione-agarose beads; and MLK4-, PAK4-, PAK5- and YSK2-polyhistidine fusions can be purified using divalent nickel resin. Alternatively, antibodies against a carrier protein or peptide can be used for affinity chromatography purification of the fusion protein. For example, a nucleotide sequence coding for the target epitope of a monoclonal antibody can be engineered into the expression vector in operative association with the regulatory elements and situated so that the expressed epitope is fused to the MLK4, PAK4, PAK5 or YSK2 polypeptide. For example, a nucleotide sequence coding for the FLAG™ epitope tag (International Biotechnologies Inc.), which is a hydrophilic marker peptide, can be inserted by standard techniques into the expression vector at a point corresponding to the amino or carboxyl terminus of the MLK4, PAK4, PAK5 or YSK2 polypeptide. The expressed MLK4, PAK4, PAK5 or YSK2 polypeptide-FLAG™ epitope fusion product can then be detected and affinity-purified using commercially available anti-FLAG™ antibodies.

[0078] The expression vector encoding the MLK4, PAK4, PAK5 or YSK2 fusion protein can also be engineered to contain sequences that encode specific protease cleavage sites so that the expressed MLK4, PAK4, PAK5 or YSK2 polypeptide can be released from the carrier region or fusion partner by treatment with a specific protease. For example, the fusion protein vector can include DNA sequences encoding thrombin or factor Xa cleavage sites, among others.

[0079] A signal sequence upstream from and in reading frame with the MLK4, PAK4, PAK5 or YSK2 ORF can be engineered into the expression vector by known methods to direct the trafficking and secretion of the expressed gene product. Non-limiting examples of signal sequences include those from  $\alpha$  factor, immunoglobulins, outer membrane proteins, penicillinase, and T-cell receptors, among others.

[0080] To aid in the selection of host cells transformed or transfected with cloning or expression vectors of the present invention, the vector can be engineered to further comprise a coding sequence for a reporter gene product or other selectable marker. Such a coding sequence is preferably in operative association with regulatory element coding sequences, as described above. Reporter genes that can be useful in the invention are well known in the art and include those encoding green fluorescent protein, luciferase, xylE, and tyrosinase, among others. Nucleotide sequences encoding selectable markers are well known in the art, and include those that encode gene products conferring resistance to antibiotics or anti-metabolites, or that supply an auxotrophic requirement. Examples of such sequences include those that encode resistance to methotrexate, G418 or mycophenolic acid, among many others.

### 5.3.2. Host Cells

[0081] The present invention further provides transformed host cells comprising a polynucleotide molecule or recombinant vector of the invention, and novel strains or cell lines derived therefrom. Host cells useful in the practice of the invention are preferably human cells, although other eukaryotic cells or prokaryotic cells can also be used. Such other transformed host cells typically include but are not limited to microorganisms, such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA vectors, or yeast transformed with recombinant vectors, among others.

[0082] Appropriate host cells can be chosen that modify and process the gene product in the specific fashion desired. Different host cells have characteristic mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, phosphorylation) of proteins. For example, expression in a bacterial system can be used to produce an unglycosylated protein product. Expression and secretion in yeast can produce a glycosylated protein product. Expression in mammalian cells can be used to ensure "native" processing of a protein product. Further, different vector/host expression systems can affect processing reactions to different degrees.

[0083] Preferred bacterial cells as host cells are strains of *E. coli*, e.g., for cloning or expression purposes. A strain of *E. coli* adapted to growth in culture and for cloning techniques can typically be used, such as, e.g., the DH5 $\alpha$  strain, which is available either from the American Type Culture Collection (ATCC), Rockville, MD, USA (Accession No. 31343) or from commercial sources (Stratagene). Preferred eukaryotic host cells include human cells, and in particular keratinocytes, although other mammalian cells and yeast cells or insect cells can also be utilized effectively.

[0084] The recombinant expression vector of the invention is preferably transformed or transfected into one or more host cells of a substantially homogeneous culture of cells. The expression vector is generally introduced into host cells in accordance with known techniques, such as, e.g., by protoplast transformation, calcium phosphate precipitation, calcium chloride treatment, microinjection, electroporation, transfection by contact with a recombined virus, liposome-mediated transfection, DEAE-dextran transfection, transduction, conjugation, or microprojectile bombardment. Selection of transformants can be conducted by standard procedures, such as by selecting for cells expressing a selectable marker, e.g., antibiotic resistance, associated with the recombinant vector, as described above.

[0085] Once the expression vector is introduced into the host cell, the integration and maintenance of the MLK4-, PAK4-, PAK5- or YSK2-related coding sequence, either in the host cell chromosome or episomally, can be confirmed by standard techniques, e.g., by Southern hybridization analysis, restriction enzyme analysis, PCR analysis, including reverse transcriptase PCR (rt-PCR), or by immunological assay to detect the expected gene product. Host cells con-

taining and/or expressing the recombinant MLK4-, PAK4-, PAK5- or YSK2-related coding sequence can be identified by any of at least four general approaches which are well-known in the art, including: (i) DNA-DNA, DNA-RNA, or RNA-antisense RNA hybridization; (ii) detecting the presence of "marker" gene functions; (iii) assessing the level of transcription as measured by the expression of MLK4-, PAK4-, PAK5- or YSK2-specific mRNA transcripts in the host cell; and (iv) detecting the presence of mature polypeptide product as measured, e.g., by immunoassay.

### 5.3.3. Expression And Characterization Of JNKKK Polypeptides

**[0086]** Once the MLK4-, PAK4-, PAK5- or YSK2-related coding sequence has been stably introduced into an appropriate host cell, the transformed host cell is clonally propagated, and the resulting cells are grown under conditions conducive to the maximum production of the MLK4-, PAK4-, PAK5- or YSK2-related gene products. Such conditions typically include growing cells to high density. Where the expression vector comprises an inducible promoter, appropriate induction conditions such as, e.g., temperature shift, exhaustion of nutrients, addition of gratuitous inducers (e.g., analogs of carbohydrates, such as isopropyl- $\beta$ -D-thiogalactopyranoside (IPTG)), accumulation of excess metabolic by-products, or the like, are employed as needed to induce expression.

**[0087]** Where the expressed MLK4-, PAK4-, PAK5- or YSK2-related gene product is retained inside the host cells, the cells are harvested and lysed, and the product is isolated and purified from the lysate under extraction conditions known in the art to minimize protein degradation such as, e.g., at 4°C, or in the presence of protease inhibitors, or both. Where the expressed MLK4-, PAK4-, PAK5- or YSK2-related gene product is secreted from the host cells, the exhausted nutrient medium can simply be collected and the product isolated therefrom.

**[0088]** The expressed MLK4-, PAK4-, PAK5- or YSK2-related gene product can be isolated or substantially purified from cell lysates or culture medium, as appropriate, using standard methods, including but not limited to any combination of the following methods: ammonium sulfate precipitation, size fractionation, ion exchange chromatography, HPLC, density centrifugation, and affinity chromatography. Where the expressed MLK4-, PAK4-, PAK5- or YSK2-related gene products exhibit biological activity, increasing purity of the preparation can be monitored at each step of the purification procedure by use of an appropriate assay. Whether or not the expressed MLK4-, PAK4-, PAK5- or YSK2-related gene products exhibit biological activity, each can be detected as based, e.g., on size, or reactivity with an antibody otherwise specific for MLK4, PAK4, PAK5 or YSK2, or by the presence of a fusion tag.

**[0089]** The present invention thus provides a substantially purified or isolated polypeptide encoded by a polynucleotide molecule of the present invention. In a specific though non-limiting embodiment, the polypeptide is a human MLK4 gene product, or a portion thereof, comprising the amino acid sequence of SEQ ID NO:2. In another specific though non-limiting embodiment, the polypeptide is a human PAK4 gene product, or a portion thereof, comprising the amino acid sequence of SEQ ID NO:4. In still another specific though non-limiting embodiment, the polypeptide is a human PAK5 gene product, or a portion thereof, comprising the amino acid sequence of SEQ ID NO:6, 8 or 10. In another specific though non-limiting embodiment, the polypeptide is a human YSK-2 gene product, or a portion thereof, comprising the amino acid sequence of SEQ ID NO:13. The present invention further provides substantially purified or isolated polypeptides that are homologous to any of the MLK4, PAK4, PAK5 or YSK2 gene products of the present invention, as homologous polypeptides are defined above. The present invention further provides peptide fragments of the MLK4, PAK4, PAK5 or YSK2 gene products or homologous polypeptides of the present invention, as peptide fragments are defined above. The substantially purified or isolated polypeptides of the present invention are useful for a variety of purposes, such as, e.g., screening for compounds that interact with MLK4, PAK4, PAK5 or YSK2 proteins, and hence are candidates for compounds that affect MLK4, PAK4, PAK5 or YSK2 activity (including the events involved in signal transduction), and for raising antibodies directed against MLK4, PAK4, PAK5 or YSK2 gene product. Such compounds and antibodies can be used in therapeutic methods to treat or prevent UV damage to the skin.

**[0090]** As used herein, a polypeptide is "substantially purified" where the polypeptide constitutes the majority (i.e., at least about 50%) by weight of the material in a particular preparation. Also, as used herein, a polypeptide is "isolated" where the polypeptide constitutes at least about 90 wt% of the material in a particular preparation. Also, as used herein, a polynucleotide molecule is "isolated" where it constitutes at least about 90 wt% of the nucleic acid material in a particular preparation, or where it appears to be separated from all other polynucleotide molecules as determined, e.g., by gel electrophoresis techniques.

**[0091]** The present invention further provides a method of preparing a substantially purified or isolated MLK4 gene product, PAK4 gene product, PAK5 gene product, YSK2 gene product or peptide fragment of the present invention, comprising culturing a host cell transformed or transfected with a polynucleotide molecule or recombinant vector of the present invention, said recombinant vector comprising a polynucleotide molecule comprising a nucleotide sequence encoding the MLK4 gene product, PAK4 gene product, PAK5 gene product, YSK2 gene product or peptide fragment, respectively, of the present invention, wherein the nucleotide sequence is in operative association with one or more regulatory elements, under conditions conducive to the expression of the particular gene product, polypeptide, or peptide fragment, and recovering the expressed gene product, polypeptide, or peptide fragment, from the cell culture in a sub-

stantially purified or isolated form.

[0092] Once an MLK4, PAK4, PAK5 or YSK2 gene product of sufficient purity has been obtained, it can be characterized by standard methods, including by SDS-PAGE, size exclusion chromatography, amino acid sequence analysis, biological activity such as kinase activity, etc. For example, the amino acid sequence of the MLK4, PAK4, PAK5 or YSK2 gene product can be determined using standard peptide sequencing techniques. The MLK4, PAK4, PAK5 or YSK2 gene product can be further characterized using hydrophilicity analysis (see, e.g., Hopp and Woods, 1981, Proc. Natl. Acad. Sci. USA 78:3824), or analogous software algorithms, to identify hydrophobic and hydrophilic regions of the MLK4, PAK4, PAK5 or YSK2 gene product respectively. Structural analysis can be carried out to identify regions of the MLK4, PAK4, PAK5 or YSK2 gene product that assume specific secondary structures. Biophysical methods such as X-ray crystallography (Engstrom, 1974, Biochem. Exp. Biol. 11:7-13), computer modeling (Eletterick and Zoller (eds), 1986, in: Current Communications in Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY), and nuclear magnetic resonance (NMR) can be used to map and study sites of interaction between the MLK4, PAK4, PAK5 or YSK2 gene products and their substrates. Information obtained from these studies can be used to select specific sites on the MLK4, PAK4, PAK5 or YSK2 gene products as potential targets for drug candidates that interact with, and alter the activity of, these gene products.

#### 5.4. Antibodies

[0093] The present invention further provides polyclonal and monoclonal antibodies that bind to an MLK4 gene product, PAK4 gene product, PAK5 gene product, YSK2 gene product, or to an homologous polypeptide or peptide fragment, of the present invention. Such antibodies can be used as affinity reagents with which to purify a native MLK4, PAK4, PAK5 or YSK2 gene product, or to analyze the activity or biological function of the MLK4, PAK4, PAK5 or YSK2 gene product.

[0094] Antibodies can be raised against any of the MLK4-, PAK4-, PAK5- or YSK2-related polypeptides of the present invention. Various host animals, including but not limited to cows, horses, rabbits, goats, sheep, and mice, can be used according to known methods to produce anti-MLK4, anti-PAK4, anti-PAK5 or anti-YSK2-specific antibodies. Various adjuvants known in the art can be used to enhance antibody production.

[0095] Polyclonal antibodies can be obtained from immunized animals and tested for anti-MLK4, anti-PAK4, anti-PAK5 or anti-YSK2 specificity using standard techniques. Alternatively, monoclonal antibodies to an MLK4, PAK4, PAK5 or YSK2 polypeptide can be prepared using any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Kohler and Milstein (Nature, 1975, 256: 495-497); the human B-cell hybridoma technique (Kosbor, et al., 1983, Immunology Today 4:72; Cote, et al., 1983, Proc. Natl. Acad. Sci. USA 80: 2026-2030); and the EBV-hybridoma technique (Cole, et al., 1985, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Alternatively, techniques described for the production of single chain antibodies (see, e.g., U.S. Patent 4,946,778) can be adapted to produce MLK4-, PAK4-, PAK5- or YSK2- specific single chain antibodies. These publications are incorporated herein by reference.

[0096] Antibody fragments that contain specific binding sites for an MLK4, PAK4, PAK5 or YSK2 polypeptide are also encompassed within the present invention and can be generated by known techniques. Such fragments include but are not limited to F(ab')<sub>2</sub> fragments, which can be generated by pepsin digestion of an intact antibody molecule, and Fab fragments, which can be generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragments. Alternatively, Fab expression libraries can be constructed (Huse et al., 1989, Science 246: 1275-1281) to allow rapid identification of Fab fragments having the desired specificity to the MLK4, PAK4, PAK5 or YSK2 polypeptide.

[0097] Techniques for the production of monoclonal antibodies and antibody fragments are well-known in the art, and are additionally described, among other places, in Harlow and Lane, 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory; and in J. W. Goding, 1986, Monoclonal Antibodies: Principles and Practice, Academic Press, London. All of the above-cited publications are incorporated herein by reference.

#### 5.5. Anti-sense Oligonucleotides And Ribozymes

[0098] Also within the scope of the present invention are oligonucleotide sequences that include anti-sense oligonucleotides, phosphorothioates and ribozymes that function to bind to, degrade and/or inhibit the translation of MLK4, PAK4, PAK5 or YSK2 mRNA.

[0099] Anti-sense oligonucleotides, including anti-sense RNA molecules and anti-sense DNA molecules, act to directly block the translation of mRNA by binding to targeted mRNA and preventing protein translation. For example, antisense oligonucleotides of at least about 15 bases and complementary to unique regions of the DNA sequence encoding an MLK4, PAK4, PAK5 or YSK2 polypeptide can be synthesized, e.g., by conventional phosphodiester techniques.



**[0100]** Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of MLK4, PAK4, PAK5 or YSK2 mRNA sequences are also within the scope of the present invention.

**[0101]** Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites that include the following sequences, GUA, GUU, and GUC. Once identified, short RNA sequences of between about 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site can be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable. The suitability of candidate targets can also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides using, e.g., ribonuclease protection assays.

**[0102]** Both the anti-sense oligonucleotides and ribozymes of the present invention can be prepared by known methods. These include techniques for chemical synthesis such as, e.g., by solid phase phosphoramidite chemical synthesis. Alternatively, anti-sense RNA molecules can be generated by in vitro or in vivo transcription of DNA sequences encoding the RNA molecule. Such DNA sequences can be incorporated into a wide variety of vectors that incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters.

**[0103]** Various modifications to the oligonucleotides of the present invention can be introduced as a means of increasing intracellular stability and half-life. Possible modifications include but are not limited to the addition of flanking sequences of ribonucleotides or deoxyribonucleotides to the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2'-O-methyl rather than phosphodiesterase linkages within the oligonucleotide backbone.

#### **5.6. Detection Of JNKKK Gene Products, And Diagnostic And Therapeutic Uses**

**[0104]** The MLK4, PAK4, PAK5 and YSK2 polynucleotide molecules, oligonucleotides, and polypeptides of the present invention, as well as antibodies of the present invention that recognize the MLK4, PAK4, PAK5 or YSK2 polypeptides, are useful in the diagnosis of diseases or conditions resulting from alteration in the expression of MLK4, PAK4, PAK5 or YSK2 gene products. Alteration in expression can be either an increase or decrease in transcription of the MLK4, PAK4, PAK5 or YSK2 gene, or an increase or decrease in translation of an MLK4, PAK4, PAK5 or YSK2 gene product. Alternatively, the presence of mutations, alleles, or polymorphisms in the MLK4, PAK4, PAK5 or YSK2 gene sequence can be correlated with diseases or conditions, including but not limited to increased or decreased susceptibility to skin damage caused by ultraviolet light or other stresses, or psoriasis.

**[0105]** Nucleic acid-based detection methods are well known in the art and include hybridization assays (e.g., Northern and Southern hybridizations, nuclease protection), polymerase chain reaction (PCR) assays, and ligation chain reaction (LCR) assays, or combinations of the above (e.g., in situ hybridization). Such assays make use of the MLK4, PAK4, PAK5 or YSK2 polynucleotides and oligonucleotides of the present invention, including complementary sequences, as described above. If analysis of an RNA gene product is desired, certain assays would typically include a reverse transcription step prior to amplification and/or hybridization, as known in the art. Such nucleic acid based techniques can be designed by those of ordinary skill in the art to assay the levels of MLK4, PAK4, PAK5 or YSK2 gene expression, or the presence or absence of particular mutations, alleles or polymorphisms.

**[0106]** Protein or polypeptide-based detection methods are also well known to those of ordinary skill and include, e.g., immunological assays such as Western blot, immunoprecipitation of labeled target, and ELISA assays. These assays use the antibodies of the present invention described above. Again, such assays can measure levels of MLK4, PAK4, PAK5 or YSK2 polypeptides expressed by a cell or organism, or the presence of mutants, alleles, or polymorphisms in the MLK4, PAK4, PAK5 or YSK2 polypeptides.

**[0107]** If an abnormal condition is associated with the over- or under-production of an MLK4, PAK4, PAK5 or YSK2 gene product, the polynucleotides and oligonucleotides of the invention can be useful in preventing, ameliorating or otherwise treating of the abnormal condition. For example, by introducing gene sequences into cells, gene therapy can be used to treat conditions in which the cells express inadequate levels of MLK4, PAK4, PAK5 or YSK2 gene product, or express abnormal or inactive MLK4, PAK4, PAK5 or YSK2 polypeptides. In some instances, abnormal conditions characterized by over-expression of MLK4, PAK4, PAK5 or YSK2 gene product can be prevented or treated using the gene therapy techniques described below. Specifically, gene therapy vectors can be designed to express anti-sense polynucleotides or ribozymes of the present invention as described above, thereby reducing the amount of MLK4, PAK4, PAK5 or YSK2 gene products that are effectively translated into polypeptide.

**[0108]** Expression vectors derived from viruses such as retroviruses, vaccinia virus, adeno-associated virus, herpes viruses, or papilloma virus can be used for delivery of recombinant MLK4, PAK4, PAK5 or YSK2 polynucleotides into the targeted cell population. Methods that are well known to those skilled in the art can be used to construct recombinant viral vectors containing an MLK4, PAK4, PAK5 or YSK2 polynucleotide. See, for example, the techniques described in Maniatis et al., 1989, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y.; and



Ausubel et al., 1989, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, N.Y. Alternatively, recombinant, non-viral vectors containing an MLK4, PAK4, PAK5 or YSK2 polynucleotide can be reconstituted into liposomes for delivery to target cells, or can be delivered as a naked polynucleotide, such as, e.g., in a "DNA Vaccine," to name just a few examples.

## 5.7. Drug Screening Applications

[0109] MLK4, PAK4, PAK5 and YSK2 gene products, including polynucleotides, oligonucleotides and polypeptides, can be used in screening assays to identify compounds that specifically bind to MLK4, PAK4, PAK5 or YSK2 gene products and thus have potential use as agonists or antagonists of MLK4, PAK4, PAK5 or YSK2 polypeptides, respectively. In a particular preferred use, the polynucleotides and polypeptides of the invention are useful to screen for compounds that affect the kinase activities of MLK4, PAK4, PAK5 or YSK2 polypeptides.

[0110] The invention thus provides assays to detect molecules that specifically bind to MLK4, PAK4, PAK5 or YSK2 polypeptides. For example, recombinant cells expressing an MLK4, PAK4, PAK5 or YSK2 polynucleotide can be used to recombinantly produce an MLK4, PAK4, PAK5 or YSK2 polypeptide, respectively, and to screen for molecules that bind to an MLK4, PAK4, PAK5 or YSK2 polypeptide, respectively. Methods that can be used to carry out the foregoing are commonly known in the art.

[0111] Diversity libraries, such as random or combinatorial peptide or non-peptide libraries can be screened for molecules that specifically bind to an MLK4, PAK4, PAK5 or YSK2 polypeptide. Many libraries are known in the art that can be used such as, e.g., chemically synthesized libraries, recombinant (e.g., phage display) libraries, and in vitro translation-based libraries.

[0112] Examples of chemically synthesized libraries are described in Fodor et al., 1991, Science 251:767-773; Houghten et al., 1991, Nature 354:84-86; Lam et al., 1991, Nature 354:82-84; Medynski, 1994, Bio/Technology 12:709-710; Gallop et al., 1994, J. Medicinal Chemistry 37(9):1233-1251; Ohlmeyer et al., 1993, Proc. Natl. Acad. Sci. USA 90:10922-10926; Erb et al., 1994, Proc. Natl. Acad. Sci. USA 91:11422-11426; Houghten et al., 1992, Biotechniques 13:412; Jayawickreme et al., 1994, Proc. Natl. Acad. Sci. USA 91:1614-1618; Salmon et al., 1993, Proc. Natl. Acad. Sci. USA 90:11708-11712; PCT Publication No. WO 93/20242, dated October 14, 1993; and Brenner and Lerner, 1992, Proc. Natl. Acad. Sci. USA 89:5381-5383.

[0113] Examples of phage display libraries are described in Scott and Smith, 1990, Science 249:386-390; Devlin et al., 1990, Science, 249:404-406; Christian, R.B. et al., 1992, J. Mol. Biol. 227:711-718; Lenstra, 1992, J. Immunol. Meth. 152:149-157; Kay et al., 1993, Gene 128:59-65; and PCT Publication No. WO 94/18318, dated August 18, 1994.

[0114] In vitro translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058, dated April 18, 1991; and Mattheakis et al., 1994, Proc. Natl. Acad. Sci. USA 91:9022-9026.

[0115] In one example, non-peptide libraries, such as a benzodiazepine library (see e.g., Bunin et al., 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712), can be screened. Peptoid libraries, such as that described by Simon et al., 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371, can also be used. Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh et al. (1994, Proc. Natl. Acad. Sci. USA 91:11138-11142).

[0116] Screening the libraries can be accomplished by any of a variety of commonly known methods. See, for example, the following references, which disclose screening of peptide libraries: Parmley and Smith, 1989, Adv. Exp. Med. Biol. 251:215-218; Scott and Smith, 1990, Science 249:386-390; Fowlkes et al., 1992, BioTechniques 13:422-427; Oldenburg et al., 1992, Proc. Natl. Acad. Sci. USA 89:5393-5397; Yu et al., 1994, Cell 76:933-945; Staudt et al., 1988, Science 241:577-580; Bock et al., 1992, Nature 355:564-566; Tuerk et al., 1992, Proc. Natl. Acad. Sci. USA 89:6988-6992; Ellington et al., 1992, Nature 355:850-852; U.S. Patent No. 5,096,815, U.S. Patent No. 5,223,409, and U.S. Patent No. 5,198,346, all to Ladner et al.; Rebar and Pabo, 1993, Science 263:671-673; and PCT Publication No. WO 94/18318.

[0117] In a specific embodiment, screening can be carried out by contacting the library members with an MLK4, PAK4, PAK5 or YSK2 polypeptide immobilized on a solid phase and harvesting those library members that bind to the polypeptide. Examples of such screening methods, termed "panning" techniques, are described by way of example in Parmley and Smith, 1988, Gene 73:305-318; Fowlkes et al., 1992, BioTechniques 13:422-427; PCT Publication No. WO 94/18318; and in other references cited hereinabove.

[0118] In another embodiment, the two-hybrid system for selecting interacting proteins in yeast (Fields and Song, 1989, Nature 340:245-246; Chien et al., 1991, Proc. Natl. Acad. Sci. USA 88:9578-9582) can be used to identify molecules that specifically bind to an MLK4, PAK4, PAK5 or YSK2 polypeptide within a cell.

[0119] In another aspect of the invention, methods for screening candidate compounds for drugs are provided. Such drugs can be used to reduce ultraviolet light-induced damage, inflammation and psoriasis, and enhance wound healing in a subject. The subject is an animal, typically a mammal, preferably a human.

[0120] For example, one can screen for compounds that affect the expression of an MLK4, PAK4, PAK5 or YSK2

gene product of the present invention by: (a) applying a test compound to a test sample; (b) determining the expression of at least one MLK4, PAK4, PAK5 or YSK2 gene product in the test sample; and (c) comparing the expression of the gene in the test sample with that in a reference sample. A specific change in the cellular level of the gene product in the test sample as compared to the reference sample indicates that the compound affects the cellular level of gene product from a JNKKK gene. By the term "a specific change in the cellular level of the gene product" is meant that the change in level occurs without alteration of overall transcription or translation levels in the cell (depending upon the gene product assayed). For example, when mRNA is measured, a compound that causes a "specific change" is not a compound that is a general transcriptional repressor. Similarly, for example, when protein levels are assayed, a compound that causes a "specific change" is not a general translational repressor. One can determine whether global effects on transcription or translation occur in the presence of a test compound by assaying for a control housekeeping gene product (e.g., glucose-6-phosphate dehydrogenase gene product or the actin gene product, to name just two examples).

**[0121]** One can also assay the effect of a test compound on the expression or cellular response of the MLK4, PAK4, PAK5 or YSK2 gene or polypeptide in the presence of, or in response to, a stress event. The stress event applied to the cells can be exposure to ultraviolet radiation. Preferred ultraviolet radiation can be UV-A with a wavelength in the range of 320-400 nm, or UV-B with a wavelength in the range of 280-320 nm, or UV-C with a wavelength in the range of 200-280 nm. Other types of stress events applied to the sample for screening purposes can be exposure to inflammatory cytokines such as TNF- $\alpha$ , IL-1, interferons, FGFs or PDGF. Still other types of stress events are heat shock, osmotic shock, exposure to toxic chemicals such as arsenic, disruption of the permeability barrier (e.g., with solvents), etc.

**[0122]** In one preferred embodiment, the method of drug screening comprises: (a) applying a test compound to a test sample; (b) exposing the test sample and a reference sample to a stress event; (c) determining the expression of at least one gene product in the test sample, wherein the transcript of the gene product comprises a sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11 and 12; and (d) determining the effectiveness of the test compound in blocking or otherwise modulating the cellular response to the stress event by comparing the expression of the gene product in the test sample with that in the reference sample. If the test compound significantly reduces the expression of the transcript in response to the stress event, the test compound is identified as a drug candidate that may be potentially effective in blocking the cellular response to the stress event. The expression of the MLK4, PAK4, PAK5 or YSK2 gene product can be determined using any of the methods described above. The most preferred gene products for use in this assay are the PAK5 and YSK2 gene products.

**[0123]** In another preferred embodiment, the method of drug screening entails: (a) applying a test compound to a test sample; (b) applying a stress event to the test sample; and (c) determining the amount of an MLK4, PAK4, PAK5 or YSK2 polypeptide in the test sample and in a reference sample, wherein the MLK4, PAK4, PAK5 or YSK2 polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NOS: 2, 4, 6, 8, 10 and 13; wherein a reduction in the amount of the MLK4, PAK4, PAK5 or YSK2 polypeptide in the test sample as compared to that in the reference sample indicates that the test compound is identified as a drug candidate that can potentially block the stress response.

**[0124]** Still another aspect of the invention is a method of screening for compounds that affect the activity of an MLK4, PAK4, PAK5 or YSK2 polypeptide. One can apply a test compound to a test sample and determine the activity of the MLK4, PAK4, PAK5 or YSK2 polypeptide in the test sample compared to that in a reference sample. A test compound that alters the MLK4, PAK4, PAK5 or YSK2 polypeptide activity in the test sample as compared to the reference sample is identified as a drug candidate that can potentially affect the activity of the MLK4, PAK4, PAK5 or YSK2 polypeptide. Each of the full-length MLK4, PAK4, PAK5 and YSK2 polypeptides is a kinase; thus, the activities of these polypeptides include kinase activity and binding to ATP and its analogs. Other activities include the ability to interact with activators that activate MLK4, PAK4, PAK5 or YSK2 polypeptide kinase activity, interaction with downstream target proteins, and interaction with inhibitors via the amino-terminal regulatory domain.

**[0125]** In another preferred embodiment, the activity of MLK4, PAK4, PAK5 or YSK2 polypeptides, such as kinase activity, binding to ATP and its analogs, or activation of downstream target protein, can be assayed in the test and reference samples in response to application of a stress event, and compared, to predict the effectiveness of the drug candidate. If the drug candidate prevents the induction of the function of the MLK4, PAK4, PAK5 or YSK2 polypeptide by a particular stress event, such as ultraviolet radiation, the drug candidate can be effective at blocking the stress response.

**[0126]** In some preferred embodiments, the test and reference samples are cultured cells, tissues or organs. In other preferred embodiments, the test and reference samples are live animals. In a particularly preferred embodiment, a small biopsy of human skin (e.g., about 5 mm<sup>3</sup>) is placed in culture and treated with, e.g., ultraviolet radiation, one or more growth factors, cytokines, drugs, hormones or vitamins. After a defined period of time (typically 24-48 hours when the treatment is ultraviolet radiation), the biopsy is tested for expression of the MLK4, PAK4, PAK5 or YSK2 gene product, or for activity of the MLK4, PAK4, PAK5 or YSK2 polypeptide.

**[0127]** The invention having been described, the following examples are offered by way of illustration and not limitation.

**6. Example: Cloning Of The YSK2, MLK4, PAK4 And PAK5 cDNAs**

[0128] This example illustrates the methods used to clone the novel JNKKKs of the invention.

**6.1. Materials And Methods**

[0129] Normal human foreskin epidermal keratinocytes were a generous gift from Dr. M. Simon of the State University of New York at Stony Brook. The cultures were initiated using 3T3 feeder layers and then frozen in liquid nitrogen until used. Once thawed, the keratinocytes were grown without feeder cells in defined serum-free keratinocyte growth medium (KGM), supplemented with bovine pituitary extract epidermal growth factor, insulin, thyroid hormone and hydrocortisone (keratinocyte-SFM, GIBCO).

[0130] Messenger RNA from the keratinocytes was used for reverse transcription polymerase chain reaction (RT-PCR) amplification with an RT-PCR kit (Promega Corp., Madison, Wisconsin). Primers corresponding to regions of homology between the kinase domains of JNKs or JNKKKs were designed to amplify a 150 bp PCR products from keratinocyte mRNA using RT-PCR. The primers contain the following sequences that correspond to the regions of the kinase domain.

Forward: 5'-ATGCA(CA)CANGA(CT)AT(ACT)AA(AG)-3' (SEQ ID NO: 14)

Reverse: 5'-GCNAC(CT)TCNGGNGCCATCCA-3' (SEQ ID NO: 15)

[0131] The actual primers used for RT-PCR also contained cloning sites. Their sequences are as follows:

Forward: 5'-CCCGAATTCATGCA(CA)CANGA(CT)AT(ACT)AA(AG)-3' (SEQ ID NO:16)

Reverse: 5'-CCCGAATTCGCNAC(CT)TCNGGNGCCATCCA-3' (SEQ ID NO: 17)

[0132] The PCR products were sub-cloned and sequenced.

**6.2. Results**

[0133] Among the seventy different clones sequenced, ten different JNKKKs were identified, four of which appeared to be novel. An amino acid sequence comparison against the protein databases in the European Molecular Biology Network (available at HYPERLINK <http://www.expasy.ch>; <http://www.expasy.ch>; <http://www.ch.embnet.org>) with other JNKKKs revealed that the four novel JNKKKs exhibited some degree of homology to various known JNKKKs from several different families. One JNKKK clone was 91% identical at positions 12-131 to a 134 base region of the murine YSK2 gene sequence (corresponding to positions 503-384 of emb: U49949, Osada et al., 1997, Oncogene 14:2047-2057); hence, this clone was designated as the human keratinocyte YSK2 (SEQ ID NO:12). Additionally, two human expressed sequence tags (ESTs) were related to the human keratinocyte YSK2. Specifically, Human EST emb:AA557573 (NCI-CGAP, "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index <http://www.ncbi.nlm.nih.gov/ncicgap>," Unpublished.) showed a 96% identity with the human YSK2 gene sequence (SEQ ID NO:12) in a 137 bp region corresponding to positions 6-142 of SEQ ID NO:12 and positions 32-168 of emb:AA557573. Human EST emb:AA578088 (NCI-CGAP, "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index <http://www.ncbi.nlm.nih.gov/ncicgap>," Unpublished.) also showed a 96% identity with the SEQ ID NO:12 in a 136 bp region corresponding to positions 6-141 of SEQ ID NO:12 and positions 35-170 of emb:AA578088.

[0134] Another JNKKK clone, designated MLK4 (SEQ ID NO:1), was 50% to 78% identical to members of the MLK family of JNKKKs. Finally, two JNKKK clones, designated PAK4 (SEQ ID NO:3) and PAK5 (SEQ ID NO:5), showed similar identity to members of the PAK family of JNKKKs. However, no homolog sequences could be found in the European Molecular Biology Network protein database for either MLK4 or PAK5. Although initial sequence searches of PAK4 indicated it was a new member of the PAK gene family, during the course of this work, the complete sequence of human PAK4 was published (Abo et al., 1998, EMBO J 22:6527-6540).

[0135] The relative abundance of the different identified JNKKKs is shown below in TABLE 1 below.

Table 1

ABUNDANCE OF DIFFERENT JNKKKS	
Kinase	Number of Isolates
BPAG1*	1
GCK	3
LIMK	1
MEKK3	4
MLK4	2
NiK	94
PAK1	40
PAK2	31
PAK4	69
PAK5	59
YSK1	1
Ysk2	51
<b>Total</b>	<b>356</b>

\*LIMK is a protein kinase, related to, but not a member of, the JNKKK family. Frangiskakis et al., 1996, Cell 86:59-69. BPAG1 is an abundant protein in basal keratinocytes. Its mRNA contains two segments recognized by the 8 bases at the 3' termini of our oligonucleotides.

[0136] The RT-PCR products (SEQ ID NOS:1, 3, 5, 12) of the MLK4, PAK4, PAK5 and YSK2 mRNAs were used as probes for Northern Hybridization to mRNAs from heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Figure 2 shows that the expression of the PAK4 gene is ubiquitous among the organs tested. However, the PAK5 gene is strongly expressed in keratinocytes and in the brain, but not expressed, or only weakly expressed, in placenta, lung, liver, skeletal muscle, kidney and pancreas. The MLK4 gene is expressed in keratinocytes, kidney and pancreas, but not in the brain, placenta, lung, liver, and skeletal muscle. The size of the transcripts of PAK4, PAK5 and MLK4 are 3.4, 4.4 and 4.8 kb, respectively.

#### 7. Example: Genomic Sequence Of The PAK5 Gene

[0137] Oligonucleotides 5'-GAGTGACTCCATCCTGC-3' (SEQ ID NO: 18) and 5'-GTAGGGGGTTCCACCA-3' (SEQ ID NO: 19) were used to identify a genomic clone from a commercially available P1 human library (Genome Systems, Inc., St. Louis, MO) that contained the PAK5 gene. The P1 genomic clone was partially sequenced, and additional coding sequence deduced. The polynucleotide sequence, with deduced exons indicated, is presented as SEQ ID NO:7. SEQ ID NO:8 presents the deduced amino acid sequence from the partial genomic sequence. A partial schematic structure of the PAK5 gene is depicted in Figure 1. A PLC-2 gene was found to be linked to the PAK5 gene in the P1 clone. The PLC-2 gene has been mapped to chromosome 15; thus, the PAK5 gene also must reside on chromosome 15.

[0138] The deduced amino acid sequence of the PAK5 protein (SEQ ID NO:8) is very similar to that of PAK4 (SEQ ID NO:4), especially in the kinase domain (amino acid residues 93 to 311 in SEQ ID NO:8). The kinase domains of any of the JNKKKs of the present invention have utility as enzymatically active domains to phosphorylate substrates. The sequence of the PAK5 kinase domain contains a conserved lysine (K) residue that is essential for ATP binding (amino

BEST AVAILABLE COPY

acid residue 120 in SEQ ID NO:8). By analogy with PAK4, mutations that change this lysine residue in PAK5 to alanine or methionine residues will abolish PAK5 enzymatic activity, while mutations that change the lysine residue to a glutamine will make a full length PAK5 protein constitutively active. Less homology between PAK4 and PAK5 is observed outside of the kinase domain. The 21 residue carboxy terminal extension of PAK5 is 4 amino acids longer than that of PAK4. Additionally, the available amino terminal sequences of the PAK5 protein bear no similarity to any known protein other than PAK4. Thus, both the carboxy terminal and the amino terminal regions of the PAK5 protein will be particularly useful in generating antibodies that immunospecifically recognize PAK5.

[0139] The ORF of the complete human cDNA sequence of PAK5 is presented in SEQ ID NO:9 from nt 199-2244. The complete DNA sequence for the human PAK5 gene is presented in SEQ ID NO:10, with the ORF from nt 6125-17433.

#### 8. Example: Ultraviolet Radiation-Induced Expression Of YSK2 And PAK5 mRNA

[0140] In this example, the effect of various wavelengths of ultraviolet radiation on the expression of the novel JNKKKs was investigated. The effects of both UV-C light (short wavelength ultraviolet radiation of 220 to 290 nm) and UV-A light (long wavelength ultraviolet radiation of 320 to 400 nm) were separately analyzed.

[0141] Keratinocytes were grown as described in Section 6.1, above. The cells were expanded through two 1:4 passages before illumination with 3-10 mJ/cm<sup>2</sup> of UV-C light or 1-5 J/cm<sup>2</sup> of UV-A light. Cells were harvested 6 or 24 hours after exposure. PolyA mRNA was purified from the cells using kits from Qiagen.

[0142] Figure 3A shows that the YSK2 gene is induced by UV-C light. Keratinocytes were exposed to 10 mJ/cm<sup>2</sup> of UV-C light. Messenger RNAs from control and UV-C light-treated cells were separated by electrophoresis and transferred to a membrane by Northern blotting. The membrane was then hybridized using the 190 bp YSK2 RT-PCR product labeled with <sup>32</sup>P-dNTPs as the probe. As Figure 3A shows, the expression of the YSK2 gene in keratinocytes was greatly enhanced by UV-C light exposure.

[0143] Figure 3B shows that the PAK5 gene is induced by UV-A light treatment. Human keratinocytes were exposed to UV-A light (5 mJ/cm<sup>2</sup>), harvested, and mRNA prepared from the cells. The levels of PAK4 and PAK5 mRNA in treated and untreated cells were compared using differential display. Liang and Pardee, 1992, Science 257:967-71. Amplification was performed using primer SEQ ID NOS:14 and 15, or SEQ ID NO:16 and 17, above. The resulting amplified DNA was then digested with restriction enzyme TaqI to reveal specifically the PAK4 and the PAK5 DNAs. The results demonstrate that PAK5 is induced by ultraviolet radiation.

[0144] Differential display experiments (Figures 3A and 3B) show that expression of both YSK2 and PAK5 genes are induced by ultraviolet radiation. However, induction of the two genes is dependent upon the wavelength of the ultraviolet radiation. YSK2 gene expression is induced by UV-C, which is the short wavelength ultraviolet radiation (220 to 290 nm). In contrast, the PAK5 gene expression is induced by UV-A, which is the long wavelength ultraviolet radiation (320 to 400 nm). The induction of YSK2 and PAK5 gene expression by ultraviolet radiation suggests that the products of the two genes are involved in the signal transduction cascade that transduces extracellular ultraviolet radiation (or other stress signals). Although MLK4 and PAK4 mRNA gene expression were not induced by ultraviolet radiation in these experiments, this fact cannot rule out a role in the keratinocyte response to light or other stresses. These gene products can be involved in the early cellular events in response to stress prior to any changes in gene expression.

[0145] The foregoing written specification is sufficient to enable one skilled in the art to practice the invention. Indeed, various modifications of the above-described means for carrying out the invention which are obvious to those skilled in the field of molecular biology, medicine or related fields are intended to be within the scope of the following claims.

[0146] All references referred to herein above are incorporated herein by reference in their entirety.

## SEQUENCE LISTING

<110> New York University

<120> GENES AND POLYNUCLEOTIDES ASSOCIATED WITH ULTRAVIOLET  
RADIATION-MEDIATED SKIN DAMAGE AND USES THEREOF

<130> PC10489A

<140>

<141>

<150> 60/155,029

<151> 1999-09-20

<160> 19

<170> PatentIn Ver. 2.1

<210> 1

<211> 164

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (2)..(163)

<400> 1

g cac cgg gac atc aag gca gga aat att ttg cta ctt gag aag ata gaa 49

His Arg Asp Ile Lys Ala Gly Asn Ile Leu Leu Leu Glu Lys Ile Glu

1

5

10

15

cat gat gac atc tgc aat aaa act ttg aag att aca gat ttt ggg ttg 97

His Asp Asp Ile Cys Asn Lys Thr Leu Lys Ile Thr Asp Phe Gly Leu

20

25

30

gcg agg gaa tgg cac agg acc acc aaa atg agc aca gca ggc acc tat 145

Ala Arg Glu Trp His Arg Thr Thr Lys Met Ser Thr Ala Gly Thr Tyr

35

40

45

gcc tgg atg gcc cca gaa g

164

Ala Trp Met Ala Pro Glu

50

<210> 2

<211> 54

EP 1 085 093 A2

<212> PRT

<213> Homo sapiens

<400> 2

His Arg Asp Ile Lys Ala Gly Asn Ile Leu Leu Leu Glu Lys Ile Glu  
1 5 10 15

His Asp Asp Ile Cys Asn Lys Thr Leu Lys Ile Thr Asp Phe Gly Leu  
20 25 30

Ala Arg Glu Trp His Arg Thr Thr Lys Met Ser Thr Ala Gly Thr Tyr  
35 40 45

Ala Trp Met Ala Pro Glu  
50

<210> 3

<211> 145

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (2)..(145)

<400> 3

a cat cgg gac atc aag agc gac tcg atc ctg ctg acc cat gat ggc agg 49  
His Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu Thr His Asp Gly Arg  
1 5 10 15

gtg aag ctg tca gac ttt ggg ttc tgc gcc cag gtg agc aag gaa gtg 97  
Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Val Ser Lys Glu Val  
20 25 30

ccc cga agg aag tcg ctg gtc ggc acg ccc tac tgg atg gcc cca gag 145  
Pro Arg Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu  
35 40 45

<210> 4

<211> 48

<212> PRT

<213> Homo sapiens

<400> 4

His Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu Thr His Asp Gly Arg

EP 1 085 093 A2

1

5

10

15

Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Val Ser Lys Glu Val  
20 25 30

Pro Arg Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu  
35 40 45

<210> 5

<211> 146

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (2)..(145)

<400> 5

t cac agg gac atc aag agt gac tcc atc ctg ctg acc ctc gat ggc agg 49  
His Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu Thr Leu Asp Gly Arg  
1 5 10 15

gtg aag ctc tcg gac ttc gga ttc tgt gct cag atc agc aaa gac gtc 97  
Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Ile Ser Lys Asp Val  
20 25 30

cct aag agg aag tcc ctg gtg gga acc ccc tac tgg atg gcg ccc gag g 146  
Pro Lys Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu  
35 40 45

<210> 6

<211> 48

<212> PRT

<213> Homo sapiens

<400> 6

His Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu Thr Leu Asp Gly Arg  
1 5 10 15

Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Ile Ser Lys Asp Val  
20 25 30

Pro Lys Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu  
35 40 45



EP 1 085 093 A2

<210> 7  
 <211> 3627  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> CDS  
 <222> (868)..(1275)

<220>  
 <221> CDS  
 <222> (1420)..(1553)

<220>  
 <221> CDS  
 <222> (1900)..(2026)

<220>  
 <221> CDS  
 <222> (2105)..(2230)

<220>  
 <221> CDS  
 <222> (2696)..(2833)

<400> 7

gatctgcgac ctccttcaga acctgccaaa atgactagga aaaatgctgt ttccatagca 60  
 agagccaaaa gagaacatga cggccctgca ctcggggatc tctctggcac cagattccca 120  
 gccagggga gacacctgaa cccccagat ggtgacacac ctctgtggtc ctctgtcagg 180  
 gacataacct cccagcacag atttgaaac tccctgctgc aggcacaagc agggctatcg 240  
 ggccccaggt gtggctcccc tgccttggtt caggagtggt agacacagtt gccactgct 300  
 cccacccca ctgccaggcc tcttctgccc ccattgggtcc tggggtgggg gagccttggg 360  
 agttgaagaa tgcctctgac ccagattctt caagcagcct ctgagctcag aggaagagtc 420  
 tgcctcacgg cagcctccct ggggtctagc tgtcaatcgc ccaggaagaa ataccagcg 480  
 cgggaccgg cggggaagct ggccttctct gtcttcccag gtgcagcaca gcgagtgtaa 540  
 ggagctgtct tgggcctgcc cagcctggtg ccctgcgggg gactgctggc acaggactgt 600

EP 1 085 093 A2

gaactgggctt cagctctgtc tgaaaatctt tgcttcagag cacctcccta gtttgatctg 660

5 ataccccgcc tgacctgcc agagtccaga ggtcacggcg gccagcccct gcctccggga 720

aggttattcc aaatgctccc acagccctga ccttctctgt tgctttgtcc cttgcagccc 780

10 aactcctctt tccgaccgcc gcagaaagac aaccccccaa gcctggtggc caaggcccag 840

tccttgccct cggaccagcc ggtgggg acc ttc agc cct ctg acc act tcg gat 894  
 Thr Phe Ser Pro Leu Thr Thr Ser Asp  
 1 5

15 acc agc agc ccc cag aag tcc ctc cgc aca gcc ccg gcc aca ggc cag 942  
 Thr Ser Ser Pro Gln Lys Ser Leu Arg Thr Ala Pro Ala Thr Gly Gln  
 10 15 20 25

20 ctt cca ggc cgg tct tcc cca gcg gga tcc ccc cgc acc tgg cac gcc 990  
 Leu Pro Gly Arg Ser Ser Pro Ala Gly Ser Pro Arg Thr Trp His Ala  
 30 35 40

25 cag atc agc acc agc aac ctg tac ctg ccc cag gac ccc acg gtt gcc 1038  
 Gln Ile Ser Thr Ser Asn Leu Tyr Leu Pro Gln Asp Pro Thr Val Ala  
 45 50 55

30 aag ggt gcc ctg gct ggt gag gac aca ggt gtt gtg aca cat gag cag 1086  
 Lys Gly Ala Leu Ala Gly Glu Asp Thr Gly Val Val Thr His Glu Gln  
 60 65 70

35 ttc aag gct gcg ctc agg atg gtg gtg gac cag ggt gac ccc cgg ctg 1134  
 Phe Lys Ala Ala Leu Arg Met Val Val Asp Gln Gly Asp Pro Arg Leu  
 75 80 85

40 ctg ctg gac agc tac gtg aag att ggc gag ggc tcc acc ggc atc gtc 1182  
 Leu Leu Asp Ser Tyr Val Lys Ile Gly Glu Gly Ser Thr Gly Ile Val  
 90 95 100 105

45 tgc ttg gcc cgg gaa gaa cac tcg ggc cgc cag gtg gcc gtc aag atg 1230  
 Cys Leu Ala Arg Glu Glu His Ser Gly Arg Gln Val Ala Val Lys Met  
 110 115 120

50 atg gac ctc aga aag cag cag cgc agg gag ctg ctc ttc aac gag 1275  
 Met Asp Leu Arg Lys Gln Gln Arg Arg Glu Leu Leu Phe Asn Glu  
 125 130 135

55 gtgggaggac aggggtggac acacacgggg gcgttgggga tgggcagtga gcagccagcc 1335

aggctggaca tctgtgagca ggggcagtgg gtggccatgc gtctgggcac tgtgcctggc 1395

**EP 1 085 093 A2**

	actcaggccc ccacctgccc ccag gtg gtg atc atg cgg gac tac cag cac	1446
	Val Val Ile Met Arg Asp Tyr Gln His	
5	140 145	
	ttc aac gtg gtg gag atg tac aag agc tac ctg gtg ggc gag gag ctg	1494
	Phe Asn Val Val Glu Met Tyr Lys Ser Tyr Leu Val Gly Glu Glu Leu	
	150 155 160	
10	tgg gtg ctc atg gag ttc ctg cag gga gga gcc ctc aca gac atc gtc	1542
	Trp Val Leu Met Glu Phe Leu Gln Gly Gly Ala Leu Thr Asp Ile Val	
	165 170 175	
15	tcc caa gtc ag gtgggcagct gggagggctg gaccctgagt gcaggctgcc	1593
	Ser Gln Val Arg	
	180	
20	ctcaccatgg ccctgccagg gcaatgtggt cttctgcctg tggcccagaa gacttgggat	1653
	gcctgggctc ccctgcctgc tggggtaact gagaccaggg ggtcttggga gtggagaaga	1713
	gaaggatagc ttctagccaa agctcaggcc ccagttttca ccagggtat ggctgactg	1773
25	tgctgcaaaa cagattgcct gggagctgtg gggcctagca ccagggactc ctactctgct	1833
	cagccacccc acgacctgcc agagctaacg ttctctttca tcgggtggcc ccaccttcct	1893
30	gtccag g ctg aat gag gag cag att gcc act gtg tgt gag gct gtg ctg	1942
	Leu Asn Glu Glu Gln Ile Ala Thr Val Cys Glu Ala Val Leu	
	185 190 195	
35	cag gcc ctg gcc tac ctg cat gct cag ggt gtc atc cac cgg gac atc	1990
	Gln Ala Leu Ala Tyr Leu His Ala Gln Gly Val Ile His Arg Asp Ile	
	200 205 210	
40	aag agt gac tcc atc ctg ctg acc ctc gat ggc agg gtaggtccca	2036
	Lys Ser Asp Ser Ile Leu Leu Thr Leu Asp Gly Arg	
	215 220	
	tcctgtccct ggcacagcca cgctcccact tcctctgat ccaccactca ctcccttttc	2096
45	aaccgcag gtg aag ctc tcg gac ttc gga ttc tgt gct cag atc agc aaa	2146
	Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Ile Ser Lys	
	225 230 235	
50	gac gtc cct aag agg aag tcc ctg gtg gga acc ccc tac tgg atg gct	2194
	Asp Val Pro Lys Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala	
	240 245 250	

EP 1 085 093 A2

cct gaa gtg atc tcc agg tct ttg tat gcc act gag gtaaccgttc 2240  
Pro Glu Val Ile Ser Arg Ser Leu Tyr Ala Thr Glu  
255 260 265

cctccacccc ccagacctcc caaaagcaac ttggcaactg gcagctcttc tgctgtggcc 2300

cctccagtga gctcaccaaaa agcagccctg gttttcagag tcccacctag tcaacaccct 2360

tcccccttcc gatggggctg ctcttaccga gtgactttgc tgccagggaac gagtcctgca 2420

agtgtcttcc tcagctcaag ggcagaatgg ggtatggccg ggcctcttat gtatgatggc 2480

ctttctctga gtgactgaca gctgtgtccc tataggcagt ggtcactcat gcaggcagta 2540

actggccaca gggcagggtga ccagggggagg aaggagacag acccaccaag gagagctggg 2600

gccagctgtc cccctccac cactgctgcc accagaacgc agctaccaat gggccagggt 2660

ctggccatgg ggtcagggac atttctctcc tgcag gtg gat atc tgg tct ctg 2713  
Val Asp Ile Trp Ser Leu  
270

ggg atc atg gtg att gag atg gta gat ggg gag cca ccg tac ttc agt 2761  
Gly Ile Met Val Ile Glu Met Val Asp Gly Glu Pro Pro Tyr Phe Ser  
275 280 285

gac tcc cca gtg caa gcc atg aag agg ctc cgg gac agc ccc cca ccc 2809  
Asp Ser Pro Val Gln Ala Met Lys Arg Leu Arg Asp Ser Pro Pro Pro  
290 295 300

aag ctg aaa aac tct cac aag gtc agttggcaca caagggtgag acctgcaga 2863  
Lys Leu Lys Asn Ser His Lys Val  
305 310

ccccattcct cctgaggcaa ggggaccaga acctgggctc ccagcatctc ccttccactg 2923

aagccacagg gtctgggctc ctggaaaagg ctctcttctc cccacacaaa accgcacct 2983

gggtgtggag ccgcatctac gcacaagtgc gcatgtgcgc tccgacaagt cgctcccccac 3043

ggctgtggca ggagagttgc tgcttggcag aagggttgct gcttggcagg cactggtcgg 3103

aagcccagtg gggcccatga gcagggaag ccaggacacc agcaactccc tgctgtccag 3163

ggagggatcc ggagaagctt cactgagcac aaacccttca acccgtgtcg ggagatccat 3223

accatgattc gatgtccctg tccatcacgg cgagtcgggt catgtccat tcgttgaca 3283

EP 1 085 093 A2

ccccgacaca gctaagccac agcgttccccc ttaaagccag tataagtgc tggagtggt 3343  
 5 ataatgttaa cccctttttgc caaatcggcc ccaaccccg aggccttact gtggacgcc 3403  
 cctgctggca ggtcagcacg gggctgataa gtggcaccgc catctggtgg ccaaaacaag 3463  
 10 aaatgtctca gagggctgaa gcctctcctc taaaatagca aaaaaacaag agttctgtgg 3523  
 ccccaacaca aagctggatg ggaggaccaa caggaaacat cttccaagac aactggtcct 3583  
 tggagcctcg accgctaacc ccaaaattag catataaagc atgc 3627

<210> 8  
 <211> 311  
 <212> PRT  
 20 <213> Homo sapiens

<400> 8  
 Thr Phe Ser Pro Leu Thr Thr Ser Asp Thr Ser Ser Pro Gln Lys Ser  
 1 5 10 15  
 25 Leu Arg Thr Ala Pro Ala Thr Gly Gln Leu Pro Gly Arg Ser Ser Pro  
 20 25 30  
 30 Ala Gly Ser Pro Arg Thr Trp His Ala Gln Ile Ser Thr Ser Asn Leu  
 35 40 45  
 Tyr Leu Pro Gln Asp Pro Thr Val Ala Lys Gly Ala Leu Ala Gly Glu  
 50 55 60  
 35 Asp Thr Gly Val Val Thr His Glu Gln Phe Lys Ala Ala Leu Arg Met  
 65 70 75 80  
 Val Val Asp Gln Gly Asp Pro Arg Leu Leu Leu Asp Ser Tyr Val Lys  
 40 85 90 95  
 Ile Gly Glu Gly Ser Thr Gly Ile Val Cys Leu Ala Arg Glu Glu His  
 100 105 110  
 45 - Ser Gly Arg Gln Val Ala Val Lys Met Met Asp Leu Arg Lys Gln Gln  
 115 120 125  
 Arg Arg Glu Leu Leu Phe Asn Glu Val Val Ile Met Arg Asp Tyr Gln  
 130 135 140  
 50 His Phe Asn Val Val Glu Met Tyr Lys Ser Tyr Leu Val Gly Glu Glu  
 145 150 155 160

EP 1 085 093 A2

Leu Trp Val Leu Met Glu Phe Leu Gln Gly Gly Ala Leu Thr Asp Ile  
165 170 175

Val Ser Gln Val Arg Leu Asn Glu Glu Gln Ile Ala Thr Val Cys Glu  
180 185 190

Ala Val Leu Gln Ala Leu Ala Tyr Leu His Ala Gln Gly Val Ile His  
195 200 205

Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu Thr Leu Asp Gly Arg Val  
210 215 220

Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Ile Ser Lys Asp Val Pro  
225 230 235 240

Lys Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu Val  
245 250 255

Ile Ser Arg Ser Leu Tyr Ala Thr Glu Val Asp Ile Trp Ser Leu Gly  
260 265 270

Ile Met Val Ile Glu Met Val Asp Gly Glu Pro Pro Tyr Phe Ser Asp  
275 280 285

Ser Pro Val Gln Ala Met Lys Arg Leu Arg Asp Ser Pro Pro Pro Lys  
290 295 300

Leu Lys Asn Ser His Lys Val  
305 310

<210> 9

<211> 2669

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (199)..(2244)

<400> 9

gagtgccgct tectgggcta gagacaagca ccagcctgca gtggagaacg caggaccccg 60

ctgcccagaa ggagcagcca cggcctgctg aggactggcc cagcaaggtc ccagggtcttc 120

cctctctctca ggccttaaga gagaggccca gtgcgggtga ggagtcgcga ggaagaggcg 180

EP 1 085 093 A2

	gaagggcgccg gaaggacc atg ttc cgc aag aaa aag aag aaa cgc cct gag	231
	Met Phe Arg Lys Lys Lys Lys Arg Pro Glu	
5	1 5 10	
	atc tca gcg cca cag aac ttc cag cac cgt gtc cac acc tcc ttc gac	279
	Ile Ser Ala Pro Gln Asn Phe Gln His Arg Val His Thr Ser Phe Asp	
	15 20 25	
10	ccc aaa gaa ggc aag ttt gtg ggc ctc ccc cca caa tgg cag aac atc	327
	Pro Lys Glu Gly Lys Phe Val Gly Leu Pro Pro Gln Trp Gln Asn Ile	
	30 35 40	
15	ctg gac aca ctg cgg cgc ccc aag ccc gtg gtg gac cct tcg cga atc	375
	Leu Asp Thr Leu Arg Arg Pro Lys Pro Val Val Asp Pro Ser Arg Ile	
	45 50 55	
20	aca cgg gtg cag ctc cag ccc atg aag aca gtg gtg cgg ggc agc gcg	423
	Thr Arg Val Gln Leu Gln Pro Met Lys Thr Val Val Arg Gly Ser Ala	
	60 65 70 75	
25	atg cct gtg gat ggc tac atc tcg ggg ctg ctc aac gac atc cag aag	471
	Met Pro Val Asp Gly Tyr Ile Ser Gly Leu Leu Asn Asp Ile Gln Lys	
	80 85 90	
30	ttg tca gtc atc agc tcc aac acc ctg cgt ggt cgc agc ccc acc agc	519
	Leu Ser Val Ile Ser Ser Asn Thr Leu Arg Gly Arg Ser Pro Thr Ser	
	95 100 105	
35	cgg cgg cgg gca cag tcc ctg ggg ctg ctg ggg gat gag cac tgg gcc	567
	Arg Arg Arg Ala Gln Ser Leu Gly Leu Leu Gly Asp Glu His Trp Ala	
	110 115 120	
40	acc gac cca gac atg tac ctc cag agc ccc cag tct gag cgc act gac	615
	Thr Asp Pro Asp Met Tyr Leu Gln Ser Pro Gln Ser Glu Arg Thr Asp	
	125 130 135	
45	ccc cac ggc ctc tac ctc agc tgc aac ggg ggc aca cca gca ggc cac	663
	Pro His Gly Leu Tyr Leu Ser Cys Asn Gly Gly Thr Pro Ala Gly His	
	140 145 150 155	
50	aag cag atg ccg tgg ccc gag cca cag agc cca cgg gtc ctg ccc aat	711
	Lys Gln Met Pro Trp Pro Glu Pro Gln Ser Pro Arg Val Leu Pro Asn	
	160 165 170	
55	ggg ctg gct gca aag gca cag tcc ctg ggc ccc gcc gag ttt cag ggt	759
	Gly Leu Ala Ala Lys Ala Gln Ser Leu Gly Pro Ala Glu Phe Gln Gly	
	175 180 185	

EP 1 085 093 A2

gcc tcg cag cgc tgt ctg cag ctg ggt gcc tgc ctg cag agc tcc cca 807  
Ala Ser Gln Arg Cys Leu Gln Leu Gly Ala Cys Leu Gln Ser Ser Pro  
190 195 200

cca gga gcc tcg ccc ccc acg ggc acc aat agg cat gga atg aag gct 855  
Pro Gly Ala Ser Pro Pro Thr Gly Thr Asn Arg His Gly Met Lys Ala  
205 210 215

gcc aag cat ggc tct gag gag gcc cgg cca cag tcc tgc ctg gtg ggc 903  
Ala Lys His Gly Ser Glu Glu Ala Arg Pro Gln Ser Cys Leu Val Gly  
220 225 230 235

tca gcc aca ggc agg cca ggt ggg gaa ggc agc cct agc cct aag acc 951  
Ser Ala Thr Gly Arg Pro Gly Gly Glu Gly Ser Pro Ser Pro Lys Thr  
240 245 250

cgg gag agc agc ctg aag cgc agg cta ttc cga agc atg ttc ctg tcc 999  
Arg Glu Ser Ser Leu Lys Arg Arg Leu Phe Arg Ser Met Phe Leu Ser  
255 260 265

act gct gcc aca gcc cct cca agc agc agc aag cca ggc cct cca cca 1047  
Thr Ala Ala Thr Ala Pro Pro Ser Ser Ser Lys Pro Gly Pro Pro Pro  
270 275 280

cag agc aag ccc aac tcc tct ttc cga ccg ccg cag aaa gac aac ccc 1095  
Gln Ser Lys Pro Asn Ser Ser Phe Arg Pro Pro Gln Lys Asp Asn Pro  
285 290 295

cca agc ctg gtg gcc aag gcc cag tcc ttg ccc tcg gac cag ccg gtg 1143  
Pro Ser Leu Val Ala Lys Ala Gln Ser Leu Pro Ser Asp Gln Pro Val  
300 305 310 315

ggg acc ttc agc cct ctg acc act tcg gat acc agc agc ccc cag aag 1191  
Gly Thr Phe Ser Pro Leu Thr Thr Ser Asp Thr Ser Ser Pro Gln Lys  
320 325 330

tcc ctc cgc aca gcc ccg gcc aca ggc cag ctt cca ggc cgg tct tcc 1239  
Ser Leu Arg Thr Ala Pro Ala Thr Gly Gln Leu Pro Gly Arg Ser Ser  
335 340 345

cca gcg gga tcc ccc cgc acc tgg cac gcc cag atc agc acc agc aac 1287  
Pro Ala Gly Ser Pro Arg Thr Trp His Ala Gln Ile Ser Thr Ser Asn  
350 355 360

ctg tac ctg ccc cag gac ccc acg gtt gcc aag ggt gcc ctg gct ggt 1335  
Leu Tyr Leu Pro Gln Asp Pro Thr Val Ala Lys Gly Ala Leu Ala Gly  
365 370 375



EP 1 085 093 A2

gag gac aca ggt gtt gtg aca cat gag cag ttc aag gct gcg ctc agg 1383  
Glu Asp Thr Gly Val Val Thr His Glu Gln Phe Lys Ala Ala Leu Arg  
380 385 390 395

atg gtg gtg gac cag ggt gac ccc cgg ctg ctg ctg gac agc tac gtg 1431  
Met Val Val Asp Gln Gly Asp Pro Arg Leu Leu Leu Asp Ser Tyr Val  
400 405 410

aag att ggc gag ggc tcc acc ggc atc gtc tgc ttg gcc cgg gag aag 1479  
Lys Ile Gly Glu Gly Ser Thr Gly Ile Val Cys Leu Ala Arg Glu Lys  
415 420 425

cac tcg ggc cgc cag gtg gcc gtc aag atg atg gac ctc agg aag cag 1527  
His Ser Gly Arg Gln Val Ala Val Lys Met Met Asp Leu Arg Lys Gln  
430 435 440

cag cgc agg gag ctg ctc ttc aac gag gtg gtg atc atg cgg gac tac 1575  
Gln Arg Arg Glu Leu Leu Phe Asn Glu Val Val Ile Met Arg Asp Tyr  
445 450 455

cag cac ttc aac gtg gtg gag atg tac aag agc tac ctg gtg gga gag 1623  
Gln His Phe Asn Val Val Glu Met Tyr Lys Ser Tyr Leu Val Gly Glu  
460 465 470 475

gag ctg tgg gtg ctc atg gag ttc ctg cag gga gga gcc ctc aca gac 1671  
Glu Leu Trp Val Leu Met Glu Phe Leu Gln Gly Gly Ala Leu Thr Asp  
480 485 490

atc gtc tcc caa gtc agg ctg aat gag gag cag att gcc act gtg tgt 1719  
Ile Val Ser Gln Val Arg Leu Asn Glu Glu Gln Ile Ala Thr Val Cys  
495 500 505

gag gct gtg ctg cag gcc ctg gcc tac ctg cat gct cag ggt gtc atc 1767  
Glu Ala Val Leu Gln Ala Leu Ala Tyr Leu His Ala Gln Gly Val Ile  
510 515 520

cac cgg gac atc aag agt gac tcc atc ctg ctg acc ctc gat ggc agg 1815  
His Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu Thr Leu Asp Gly Arg  
525 530 535

gtg aag ctc tcg gac ttc gga ttc tgt gct cag atc agc aaa gac gtc 1863  
Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Ile Ser Lys Asp Val  
540 545 550 555

cct aag agg aag tcc ctg gtg gga acc ccc tac tgg atg gct cct gaa 1911  
Pro Lys Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu  
560 565 570

EP 1 085 093 A2

gtg atc tcc agg tct ttg tat gcc act gag gtg gat atc tgg tct ctg 1959  
Val Ile Ser Arg Ser Leu Tyr Ala Thr Glu Val Asp Ile Trp Ser Leu  
575 580 585

ggc atc atg gtg att gag atg gta gat ggg gag cca ccg tac ttc agt 2007  
Gly Ile Met Val Ile Glu Met Val Asp Gly Glu Pro Pro Tyr Phe Ser  
590 595 600

gac tcc cca gtg caa gcc atg aag agg ctc cgg gac agc ccc cca ccc 2055  
Asp Ser Pro Val Gln Ala Met Lys Arg Leu Arg Asp Ser Pro Pro Pro  
605 610 615

aag ctg aaa aac tct cac aag gtc tcc cca gtg ctg cga gac ttc ctg 2103  
Lys Leu Lys Asn Ser His Lys Val Ser Pro Val Leu Arg Asp Phe Leu  
620 625 630 635

gag cgg atg ctg gtg cgg gac ccc caa gag aga gcc aca gcc cag gag 2151  
Glu Arg Met Leu Val Arg Asp Pro Gln Glu Arg Ala Thr Ala Gln Glu  
640 645 650

ctc cta gac cac ccc ttc ctg ctg cag aca ggg cta cct gag tgc ctg 2199  
Leu Leu Asp His Pro Phe Leu Leu Gln Thr Gly Leu Pro Glu Cys Leu  
655 660 665

gtg ccc ctg atc cag ctc tac cga aag cag acc tcc acc tgc tga 2244  
Val Pro Leu Ile Gln Leu Tyr Arg Lys Gln Thr Ser Thr Cys  
670 675 680

gcccacccca agtatgctg ccacctacgc ccacaggcag ggcacactgg gcagccagcc 2304

tgccggcagg acttgctgc ctctctctct cagtattctc tccaaagatt gaaatgtgaa 2364

gccccagccc caccctctgc ccttcagcct actgggcccag gccggacctg cccctcagt 2424

gtctctccct cccgagtcct caagatggag accctttct acaggatgac cccttgatat 2484

ttgcacaggg atattttctaa gaaacgcaga ggccagcgtt cctggcctct gcagccaaca 2544

cagtagaaaa ggctgctgtg gttttttaaa ggcagttgtc cactagtgtc ctaggccact 2604

gcagaggggca gactgctggt ctccacagat acctgctgtt ctcagctcca gtttcaaacc 2664

tcgag 2669

<210> 10  
<211> 681

EP 1 085 093 A2

<212> PRT

<213> Homo sapiens

<400> 10

Met Phe Arg Lys Lys Lys Lys Lys Arg Pro Glu Ile Ser Ala Pro Gln  
 1 5 10 15  
 Asn Phe Gln His Arg Val His Thr Ser Phe Asp Pro Lys Glu Gly Lys  
 20 25 30  
 Phe Val Gly Leu Pro Pro Gln Trp Gln Asn Ile Leu Asp Thr Leu Arg  
 35 40 45  
 Arg Pro Lys Pro Val Val Asp Pro Ser Arg Ile Thr Arg Val Gln Leu  
 50 55 60  
 Gln Pro Met Lys Thr Val Val Arg Gly Ser Ala Met Pro Val Asp Gly  
 65 70 75 80  
 Tyr Ile Ser Gly Leu Leu Asn Asp Ile Gln Lys Leu Ser Val Ile Ser  
 85 90 95  
 Ser Asn Thr Leu Arg Gly Arg Ser Pro Thr Ser Arg Arg Arg Ala Gln  
 100 105 110  
 Ser Leu Gly Leu Leu Gly Asp Glu His Trp Ala Thr Asp Pro Asp Met  
 115 120 125  
 Tyr Leu Gln Ser Pro Gln Ser Glu Arg Thr Asp Pro His Gly Leu Tyr  
 130 135 140  
 Leu Ser Cys Asn Gly Gly Thr Pro Ala Gly His Lys Gln Met Pro Trp  
 145 150 155 160  
 Pro Glu Pro Gln Ser Pro Arg Val Leu Pro Asn Gly Leu Ala Ala Lys  
 165 170 175  
 Ala Gln Ser Leu Gly Pro Ala Glu Phe Gln Gly Ala Ser Gln Arg Cys  
 180 185 190  
 Leu Gln Leu Gly Ala Cys Leu Gln Ser Ser Pro Pro Gly Ala Ser Pro  
 195 200 205  
 Pro Thr Gly Thr Asn Arg His Gly Met Lys Ala Ala Lys His Gly Ser  
 210 215 220  
 Glu Glu Ala Arg Pro Gln Ser Cys Leu Val Gly Ser Ala Thr Gly Arg  
 225 230 235 240  
 Pro Gly Gly Glu Gly Ser Pro Ser Pro Lys Thr Arg Glu Ser Ser Leu  
 245 250 255  
 Lys Arg Arg Leu Phe Arg Ser Met Phe Leu Ser Thr Ala Ala Thr Ala  
 260 265 270  
 Pro Pro Ser Ser Ser Lys Pro Gly Pro Pro Pro Gln Ser Lys Pro Asn  
 275 280 285  
 Ser Ser Phe Arg Pro Pro Gln Lys Asp Asn Pro Pro Ser Leu Val Ala  
 290 295 300  
 Lys Ala Gln Ser Leu Pro Ser Asp Gln Pro Val Gly Thr Phe Ser Pro  
 305 310 315 320  
 Leu Thr Thr Ser Asp Thr Ser Ser Pro Gln Lys Ser Leu Arg Thr Ala  
 325 330 335  
 Pro Ala Thr Gly Gln Leu Pro Gly Arg Ser Ser Pro Ala Gly Ser Pro  
 340 345 350

Arg Thr Trp His Ala Gln Ile Ser Thr Ser Asn Leu Tyr Leu Pro Gln  
 355 360 365  
 Asp Pro Thr Val Ala Lys Gly Ala Leu Ala Gly Glu Asp Thr Gly Val  
 370 375 380  
 Val Thr His Glu Gln Phe Lys Ala Ala Leu Arg Met Val Val Asp Gln  
 385 390 395 400  
 Gly Asp Pro Arg Leu Leu Leu Asp Ser Tyr Val Lys Ile Gly Glu Gly  
 405 410 415  
 Ser Thr Gly Ile Val Cys Leu Ala Arg Glu Lys His Ser Gly Arg Gln  
 420 425 430  
 Val Ala Val Lys Met Met Asp Leu Arg Lys Gln Gln Arg Arg Glu Leu  
 435 440 445  
 Leu Phe Asn Glu Val Val Ile Met Arg Asp Tyr Gln His Phe Asn Val  
 450 455 460  
 Val Glu Met Tyr Lys Ser Tyr Leu Val Gly Glu Glu Leu Trp Val Leu  
 465 470 475 480  
 Met Glu Phe Leu Gln Gly Gly Ala Leu Thr Asp Ile Val Ser Gln Val  
 485 490 495  
 Arg Leu Asn Glu Glu Gln Ile Ala Thr Val Cys Glu Ala Val Leu Gln  
 500 505 510  
 Ala Leu Ala Tyr Leu His Ala Gln Gly Val Ile His Arg Asp Ile Lys  
 515 520 525  
 Ser Asp Ser Ile Leu Leu Thr Leu Asp Gly Arg Val Lys Leu Ser Asp  
 530 535 540  
 Phe Gly Phe Cys Ala Gln Ile Ser Lys Asp Val Pro Lys Arg Lys Ser  
 545 550 555 560  
 Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu Val Ile Ser Arg Ser  
 565 570 575  
 Leu Tyr Ala Thr Glu Val Asp Ile Trp Ser Leu Gly Ile Met Val Ile  
 580 585 590  
 Glu Met Val Asp Gly Glu Pro Pro Tyr Phe Ser Asp Ser Pro Val Gln  
 595 600 605  
 Ala Met Lys Arg Leu Arg Asp Ser Pro Pro Pro Lys Leu Lys Asn Ser  
 610 615 620  
 His Lys Val Ser Pro Val Leu Arg Asp Phe Leu Glu Arg Met Leu Val  
 625 630 635 640  
 Arg Asp Pro Gln Glu Arg Ala Thr Ala Gln Glu Leu Leu Asp His Pro  
 645 650 655  
 Phe Leu Leu Gln Thr Gly Leu Pro Glu Cys Leu Val Pro Leu Ile Gln  
 660 665 670  
 — Leu Tyr Arg Lys Gln Thr Ser Thr Cys  
 675 680

<210> 11  
 <211> 19038  
 <212> DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 11

5 tccccaccaa aaaattgtgc ccaagaaacc gtctgtgtcc cctgtgccaa ggtttcggtt 60  
 ttaaagaaac cccccaaaca gggaaacctt ctttcttaaa ttggtttggg tgtgaacctt 120  
 tcccttccaa gtcttgggca tcccccaaaa tcaattcatg cgttagccaa ccagaaaaat 180  
 gcctgcaacc atccaaaaga aaaaagttaa aagcagtctc accacaggca agtgcttttc 240  
 10 aagcttaggt tgaattctca agtgtgccct ccttccccctg tgtaagcca aggtttcagc 300  
 cagaaggggc ttgggcctgt gcccaacctg cccacccccg ttttgctttg tttccacttc 360  
 aggggtctaag gctcacatca tctcttttca agctggcaag gagaaacggc aggggtctggc 420  
 tctctgaggg ggagtcctt tctttcttct tontgggtgc tctttgtagg aaagctctc 480  
 ccctagatga attgcgtgca gatggagatg ctgagggggc gacagtaaca gctggcatgg 540  
 15 cctgtttgac ttaaccttg ggccccatgg ctgggtgcagc agccacctcc ctgagcccag 600  
 tggccttggg gacatggatg ggaaaaggag ccctggaaat ggcaagcgga ggccctggct 660  
 gaccgggtgg gagtgcctg aggcacacagc ctgatgctgg ggagaggcag ggcattgttt 720  
 gtcttggtg attcactcgc gatgactggg gcaacactgg tcccgttcag gtgatgaac 780  
 20 gtctcttagg cactcagcct ccatggatca ctcttctctg tatttaaaaa tattttgttt 840  
 ttggccggac gcggtggctc acgcctgtaa tcccagcact ttgggaggct gaaggcgggt 900  
 ggatcacctg aggtcaggag ttcaagatca gccagccaa catggtgaaa ccctatctct 960  
 actaaaaata caaaaattag ccggacgtgg tgggtgcacac ctatagtctc agctacttgg 1020  
 gaggctgagg caggagaatc acttgaacct ggaaggcaga ggttgcaagt agccaagatc 1080  
 25 gcaccactgt actccagcct gggcaacaga gtgaaacgct gtctcaaaaa aaaaaaaaaa 1140  
 aaaaaaaaaa tgttttttt tagagaagca atccgtcgtc ttaaggaaa acttagaaaa 1200  
 agagtgaata gatagaatag aaggagatca cctgtagccc caccaggtaa atgggacaac 1260  
 taatatgttg atgtattcc ttcaaatagc cattgtattc aactgcatt gacaaattac 1320  
 cattggcaaa atctttaaaa accccctacc cctaactat atcatcaaga attccacttt 1380  
 30 cgccaaagta aaccttgata gtttaattg tgtctgggac ccatgactgt ggacagggtt 1440  
 agggccccagc aggtcgtggg atccaggaga gaccacaaa tcgggccccct cataatgatc 1500  
 acactagacc tgagggaggt gagagtcagg ctacgggtac ccgcgcgcac tcccaccagc 1560  
 tttattattt tacctttcac attgagggtt gtgatctgtc tgcataattt tggagtatga 1620  
 tatgagctca ttcttcggg tttatttttt ttccatgcag atatcaaat acttcagta 1680  
 35 catttattaa aaacatcatc cattccccca gcattgttga gggtcacctt tgtcattaat 1740  
 caaatgacct cataagagt ggtctatttt tggattctct cttctgttcc attggtctat 1800  
 ttgtcaattc cgtactaaat ttgccaat ttgcctattt gcctattgcc tatttgccaa 1860  
 ttccatacta aattaattat ttagcttttc taataaatct taatatctat ttagtacaat 1920  
 40 cctccaactt cgttcattaa gattgtcttg gctattctct gttctttata tttctgtata 1980  
 cattttagaa tcagttcatc aatttctacc aaaggaaata tgctgggatt ttgtttgaga 2040  
 tttaaattaa tctgcagggt aacttgggaa taattgacat ctttacagta ttgaaccttc 2100  
 tcatctatga acattcttta atatctttaa taatgttttg tattttccaa tataaggact 2160  
 ttgtattttt ttgttagatt tattctagat atttgtatt ttaaatgtaa aatgatctct 2220  
 45 ttttaaaaaat ttcattttt tttttgagac agagtctcgc tctgtcgcgc aggttgaat 2280  
 gcagtggcct gatctcagct cactgcaagc tccgcctccc aggttcacgc cattctctg 2340  
 cctcagcctc ctgagtagct gggactacag gtgccacca ccacaccgg ctaattgttt 2400  
 gtagttttag tagagacggg gtttcaccgt gtagccagg atgatctcta tctctgacc 2460  
 tctgtattcg cccacctcg cctcccaaag tgctgggatt acaggcgtga gccaccgcgc 2520  
 50 ctggcccttt ttaaaaattt catgttggtta ctggtatgta gaaatccagt tgatttttta 2580  
 aaatattgac cttgagcctg ggcacgggtg ctcatgcctg taatcccagc actttgggag 2640  
 gctgaggcgg gtgatcatg aagtcaagag atcgagacca tcctggccaa catggtgaaa 2700

ccccatctct actaaaaata caaaaattag ctgggcgtga tggcgtgcgc ctgtagtccc 2760  
 agctactcag taggctaagg caggagaatc acttgaaccc gggaggcaga gattgcagtg 2820  
 agctgagatc acaccactgc actccagccc gggcaagaca gcgagactcc atctcaaaaa 2880  
 5 atatatatat atatattgac cttgaatcag ggaccttcta aattcactcc cttaaatccca 2940  
 gttttatgta gattctcccg cattttctac ttacacagtt atgttgtecc acacagtgtt 3000  
 ggctcacca catttcagat gagtcctagc tgctccctt taggtggttg attggttgat 3060  
 ttccagacc taagtgatgg cctctggtt ctaaagctct actccctagc ccccaaagcc 3120  
 10 tgagctcagc tgattgcttc tgccaactcc caccctcacc atcaccactc ctggccctgg 3180  
 gacaccctct gggctgtcct tctttcttct ccagcctccc tgctgectct gggaagaact 3240  
 tgttccggaa tggctcacta ttagaatgga ctcaagagag gctcccagag tcagagacca 3300  
 tttgctaaag atgctctccc tgtcatccc cacagcaaaa gctgagcgtc tgggtggggc 3360  
 aggggagttg gggagagggc tgttctgggg tgggtggtgg ggggccggtt caccagctct 3420  
 15 tcttcagctg cagtctgtgt ccctgcacct ccagaagatt tcacagagct agggaggagg 3480  
 gcgaacaggc cagctcaact aatccaggga tagcaggtct atccaaggga ctgggggaat 3540  
 agacctgctg aataaagact cttctgtagc aaaaggcaaa ggctgtaatc ccagcacttt 3600  
 gggagaccaaa ggcaggtgga tcatttgaag tcagaagttc gagaccagcc tggccaacat 3660  
 ggtgaaatcc cgtctctact aaaaatacaa aaattagccg ggtatgttg tgggtgcctg 3720  
 20 taatctcagc tattcaggag gctgaggcaa gagaatcact tgaacccggg aggtggaggt 3780  
 tgcagtgagc ccagatggtg ccactacact ccagtctggg cgacagggcg gcaagactcc 3840  
 ttctcaaaaa caacaacaac aacaacaaa aacaacaaaa aaggcaagg ccaaaaggag 3900  
 gaggacaaat ttaccaaaac catgatgtat atatggcgag gtccccaggt cccagacccc 3960  
 25 tgacatcagg catgaccctt ttgactggtg agtctgagca gaaagtgggt tgggtgttact 4020  
 cccagacttg tatctgccc aagtccagtg tctggagggc ctgagcttca agacagggat 4080  
 tcaaagagag gtgacatcac aagagaaaca accgtcatgt atggggactc tgcttacttc 4140  
 acacacccta aacctatga gctgtcttct attaaccccc ctggtctaga tcatttcagt 4200  
 tatttgttca aaatctctcc aaattattag tgggagactc cctacaactc atctgcaact 4260  
 30 cacacagggt gttttattcc aaagggttg gtctgtaagg gtctgtaca tgtggctcta 4320  
 cctctagggg gtgttcggtg gatcccgaa ctcaagacc agaagcatgg ctgacattga 4380  
 gatgtgacgt gggctctgat tgagtcacgc atggtgaatt cctagtgggg aaccactggc 4440  
 tgtccagggt ccctgccttt ctgccagct cctcccagat ctgcgacctc cttcagaacc 4500  
 35 tgccaaaatg actaggaaaa tgctgtttcc atagcaagag ccaaaagaga acatgacggc 4560  
 cctgcactcc agatcttcgg gcggatgagt aatccaagct ttcagttcaa gaatcatgtt 4620  
 tcagtttctt gaagcctgga agtgaccttt tcagatacat aagaaccagc tgagctgttc 4680  
 tgagcctctt cagatccaaa agcattcaag aggcagccct ggccctgtct gccatcaaca 4740  
 tgtgatccca ggtccgggat cccctgaagg cgaaactaga gcaacccttt ggaagtgtcc 4800  
 40 ctccccctcc caggccccc gttccccact ctcagatcta cccatgctat ccattgcaag 4860  
 cctgtgtcac ttctgtgtat gcagctcagc acgaccttag gcaaagccag aatcagcaag 4920  
 gcacgggaca caggcttgat tgcaggttaa gtgttttatt gtttgtttt tgagacagag 4980  
 tctcattctg ttgccaggc tggagtgcag tggggcaatc tcagctcact gcagcctcag 5040  
 cctcctgggt tcaagcgatt ctctcctc aaccccatgg gtatccggga ctacaggcac 5100  
 45 gtgccaccag gcccggttaa tttctttgta tttttagtca agacaggttt tcaccatgtt 5160  
 ggccaagctg gtctcaaact cctgacctca ggtgatccac ccgcctcggc ctcccagagt 5220  
 actaggatta caggcatgaa ccaccatgcc cggcccaggt gatgttttac atagagctcc 5280  
 aataccagag agaagagtgt caaggggagg tgggtgctct tgccctctct ggagagcttt 5340  
 acccctaagt tagctgcccc tcaccacccc caggctatcc tcttggctca gggcctttct 5400  
 50 ggaattgagg taaagcacat ggtaaccatg aaggcccttt gggggctccc tgatacataa 5460  
 tagtcccaca ccgggcagca tgtctgtgat cagctggttg gctttttatt aacgtatcat 5520  
 attaacaggt tcaaccatcc tgggacaaag ctgagttgta ataaaaaaaa aaagccaaca 5580

aaaaaataac tttatatac tgttgattc aattcgatag ttttaagatt ttcatagtta 5640  
 cgttcctaaa tgatattgag tcaaatttcc cttttcttgc actctcctta tctggtttta 5700  
 5 agaatcaagg tcataactgt ttcataaaac aagcttgcta actttcctcc ctctttcccc 5760  
 atttttaaaa ttcgttgaca gacagtggaa tgatacttgt aatgggcttt ggattttata 5820  
 aaaacacacc cccagagtct gcctgtcca taggggactt ggcacaggca agaagacacc 5880  
 tcttttcctt gtttatagtc tgcactggct tatttatggc acgtttgttg tttctgggac 5940  
 tgttctgctg ggagccagcc atttccctga ggaagcagag atgaagggtg aggcaagccc 6000  
 10 taggcttcta ggggagctgt gctgggggag gggagggagc cctgaacctg gtgccccagg 6060  
 ccctgtgca gccacccctc tttcccggga gggagctcaa ccttactctg cacttacagg 6120  
 caccatgttc cgcaagaaaa agaagaaacg ccctgagatc tcagcgccac agaacttcca 6180  
 gcaccgtgtc cacacctcct tcgaccccaa agaaggcaag tttgtgggcc tccccccaca 6240  
 atggcagaac atcctggaca cactgcggcg cccaagccc gtggtggacc ctctcgcaat 6300  
 15 cacacgggtg cagctccagc ccatgaagggt aagaggggcc ggcagggatg aggttcagcc 6360  
 tctcccagta ctacagacaac catgcctggc taaacctcag aaaggccctt ggaggaacca 6420  
 cctacttcac agctatcagt taatcagctg ttttaactcc ctgcctgtca gcctgccatt 6480  
 ctctccctgg gtaagccagg gcgaaggagg ctggggagac cctctctgca ggggtggtggg 6540  
 gtgcccagat tcagcacatg aaaatgtgag atgtcaatt gcatttgtat ttcagatgac 6600  
 20 aacgaatagt cttttaggac gtgtccatt caatatttg accctgcagcc ccatagggac 6660  
 tgagggctct cccagaccag gagaatttta gttgtgaggg tcacgactag tagaccaag 6720  
 agcctggtag aaggtggggg caggggccct atcagggttt ggaggctgcg aagccagtgt 6780  
 gtgtggagga gccccggcc tgggtgtctt tctcagagg gctgggcaca tctctccag 6840  
 25 ccaccctgtg agctagagaa tggagccccg cccctgagc tccagctccc tggcccagcc 6900  
 gaccacaccc ctgggcatgc tggatgcagc ccatggcac tcaccatctg ctctgctgac 6960  
 gctgggctt ctccccgat ccctgcattc agcacaggcg ggaccacag tgggcccctga 7020  
 taaattatgg aaaaattaat ggggtgatga cacagcaggg aaggtcctta ggtggtctc 7080  
 cccagggccc ccaggacat tctctgaccc tgatctccca gccacccctc cctgccacaa 7140  
 30 ttgggcagct cccacacact cttttctctt cccctacag acagtgggtg ggggcagcgc 7200  
 gatgctgtg gatggctaca tctcggggt gctcaacgac atccagaagt tgctagtcac 7260  
 cagctccaac accctgcgtg gccgcagccc caccagccg cggcgggcac agtccctggg 7320  
 gctgtgggg gatgagcact gggccaccga cccagacatg tacctccaga gccccagtc 7380  
 tgagcgcact gacccccacg gcctctacct cagctgcaac gggggcacac cagcaggcca 7440  
 35 caagcagatg ccgtggccc agccacagag cccacgggtc ctgcccaatg ggctggctgc 7500  
 aaaggcacag tccctgggc ccgcaggtt tcagggtgct tcgcagcgt gtctgcagct 7560  
 ggggtcctgc ctgcagact ccccaccagg agcctcgccc cccacgggca ccaataggca 7620  
 tggatgaag gctgccaaac atggctctga gaggcccg ccacagtcct gcctgggtgg 7680  
 40 ctacagccca ggcaggccag gtggggaagg cagccctagc cctaagaccc gggagagcag 7740  
 cctgaagcgc aggtattcc gaagcatgtt cctgtccact gctgccacag cccctccaag 7800  
 cagcagcaag ccaggccctc caccacagag caaggtaagt caggagcctg gcctgcaggt 7860  
 gtccactggg gagtgggtgt agggacacag gccttgcta gccttcccct tggaggactg 7920  
 gcaaagaggc tccctggact gcttccgctt aaggcggcag aaatgtgcac ggtaacctct 7980  
 45 tctctaagga ggggtgctcg cctctcctt cctcccttc ctttcttct tttctctgtg 8040  
 gctgttgtgt tgtttcccat ttctgtcagt atttgttccc aagtgtgtgg ccataggaaa 8100  
 agctggattt gcctagtcca ggggcagcag gaggccgact tgtggcatgt gtgactgctt 8160  
 cagacgcaca ttttcttgt gagaaaggaa agggtaagg gagccccctt ggtgacattt 8220  
 cttggcaggc agagtggagc gcacctttt gcttcttcca ggccctccag catcctgttg 8280  
 50 atagtacag taacctctt tccatttgg cagaggagga gactgataga gagagggtga 8340  
 gtcaccccca ggcagatgag agagtgaagc agagaaggaa ggtggggagt gctctggggc 8400  
 tgccctgtccg gcccgggccc tcttggtca tgactcttgc gtatgaaggc ttacaagca 8460

EP 1 085 093 A2

cagcagccac ttgttcttta gctccttcct gggagggtca aaggcagtc taagaaacgg 8520  
 ctgctgacag tggcatgggt aatggagcct cccctccctc ctgggagggc ttttaagacaa 8580  
 gcctgggtac tccctgtca tcggtgggt gagtgtggcc cagcctgcac aggggtgtggg 8640  
 5 tttggggatg acccggacta caacctctct gggtcactgc ctgccagctg aggtactcag 8700  
 agaaagtctt gggcgccgc gcgtggtggc tcacgtctgt agtcccagca ctttgggagg 8760  
 ccaaggtgga tgggtcacga ggtcaggaga tcgagaccat cctcgctaac acggtgaaac 8820  
 cccgtctcta ctaaaaatac aaaaaaatt agccggggcg ggtggcgggc gcctgtagtc 8880  
 10 caagctactc aggaggctga ggcaggagaa tggcgtgaac ccgggaggca gagcttgccg 8940  
 tgagctgaga tcgcaccact gcactccagc ctgggggaca gacagagcga gactccgtct 9000  
 caaaaaaaaa agagaaagtt ctgagctttg tgcactctag tcccctacta ggttaaagga 9060  
 cagtgggttg ggtaccccat ggggtgtggc ttgatgtatc tgtgagagga acacgagcat 9120  
 ctgtgagctg caggggtgtct ggaaggtgt gccctgggg agactcagcc agaaaaccaa 9180  
 15 cgtaagatca ggacagtga ccctgctggg aaggtgagat tcggagcttg acctccctct 9240  
 gtctctcag agtctgtct cgaggcctca gggatttggg gaaaggggtt gtcaacactg 9300  
 ggctgggcac tcatttgcac ctttctgggc tectgccagc accccacagc agggggagag 9360  
 gcctgtccat cctgcacaa tgtactgagt actcaccatg ggccactgct gctgggtatg 9420  
 20 ccgggatgtc cccatactt gtgggagcag gcggtagtta tctcgagctc agcaacacca 9480  
 tacttccaaa tccaggggag tggtttcctt ctgggcaact cagacacatc tttcaagatt 9540  
 tctactctga agccaagcct ctcaatggca agctgagacc ccccgagctg ctccgggccg 9600  
 gggcttctca gcgtcctcac tgcaggegt caggtcagtc catccttgt ggtgggctct 9660  
 ccttgactg tagcagcctc cctggcctct actcactaga agttggtggt accctcggtt 9720  
 25 ggaataacca aaaatgcctc cagacactgc caaatgtcac tcgagcacac cattaagaa 9780  
 ccactgcctt aagcaaattc aataacagat ggggagcatc agccttcctc ctctcctcc 9840  
 accaccacct accccaggag tcccagatc aagccagcag cccttgccac tggggctgac 9900  
 tctggacact tgcagcagct tccataacag cagttaggcc acagaggcca tgcagtgtgc 9960  
 30 caggcatggc tgcaggaggg tctgagtata gactccaggg ctctgtacc tagccccagg 10020  
 cagtgaaggc tggagtcaat ctagttaaag agatcaggaa gacagggcgt gggggcacag 10080  
 agaccaaaaga ggcaagacag ttttttagga gcttgaggg attagacatg ttccacttag 10140  
 agtcagaagg gcaaacattg gttaaagacc taccgtgtac tccgatatat gtcaaggata 10200  
 catggcacca gtgggattgc agcatgggag tcagcagcca cgggcgtcct ggggttcca 10260  
 gtgcctacag gacaacaaa caaccacag ggttatgagg attacatgag atagtacgtt 10320  
 35 gaaggcactt gtcaaaagtg taagccctca ataaatggct ttattagtag tatttgagat 10380  
 ggcgtctccc tctttcgccc aggttgagt gcagtggcac aatcttggt cactgcaacc 10440  
 tccacctcct gggttcaagt gatcctccca ccttagcctc ccaagtagct gggattacag 10500  
 gcacgctcca ccatacccaa ctaatttttg tatttttaga agagatggg tttcaccatg 10560  
 40 ttgcccaggc tggctctgaa ctctgacct caagtgatec acctgccttg gcctcccaa 10620  
 gtgctgggat tacaggcacc tgagccacca tgccaggccg gctttattat ttttaaaaat 10680  
 attatgccat ggctctccc etttaggata cttaaggat agccccctaa gccacagct 10740  
 ggggagccat ggctcagggc gggaaatgag gcattgctgt aaatgtatgc atgactctt 10800  
 tagtggcttt ctcccaaga ggtctatcac atgagtaact tcagaattaa tccagagcct 10860  
 45 gtaacaatta attaatctg ttgtcgtgtc cccctttccc tttcttgtgt ggctcacia 10920  
 gtttcatctg gtcttgtct gtgattacat tgataaaagc tccctccctg tggagacagg 10980  
 cagtgaagcc aacgaaagga tgctagagac cagacctgc caggctgaag accaagccag 11040  
 ctccccagac tccccagcct atgtcccaga ctctgcttgt gctgggctcc tggctgggcc 11100  
 atccctcccc cagcctccag acgcaggctc cgccctgagc ccagccagca cctgcagcag 11160  
 50 cagcagcagc acagggacct ggctgtgga gacagggag aaaccctac ctacgctgt 11220  
 ccacgtggta cccacacatc ctacagtag agctggccca tgcagaagcc ctcaaggcca 11280  
 ggaggggaat gatctcattt tacagcctt cttaggagct tcaggatgag aggtcatcag 11340



agccacctca ggaggagctt taggtggtcc ccaagcttct gccccgaccc acctggatgg 11400  
 gtgectggag agcatgtttt ctgagttaag tccacactca ggccagcagg cagcttctt 11460  
 5 agagccccga gcctttctac aggttgactg tgtgatgcag tgagccctgc cccacttccc 11520  
 tccctgtccc tgccctggtga cgtctcatgg aacctctgtt cccaggacct ggtatcacag 11580  
 cctcagtcac ggccatgcgc cctccacccc cctcacagcc ctccagagg ctccctgagg 11640  
 ccgtaagatc atactgccc cttatgcaga gtttctcaaa gtatgttcca tgggctctct 11700  
 aggacccagg gaccttgttc aaatgcagtc tctgctctag gctccaccg aatcaggctc 11760  
 10 tgaggcggga agtctgcggt ttctctagct cccagatct ctgcacacgt cctgcattg 11820  
 tagtgagac aggtcagag aggatgactt gcctaaggct catcacaggg cagagcagcc 11880  
 cagggtggg cccaggtcc tgacagccc gtccagggt cccactgtc cactacacag 11940  
 tggatggtga cagtgtcaca gtgtcacagt ggatggtgac agtcagggtc tggcgaggac 12000  
 atgggagaat gtttactgtc caaatgtact catcagggtt ggagtgaagc caggcagtc 12060  
 15 tgggaggatt gctagcttct tccctgtgaa ggtcaagcac aactcgggtt gggcaggcag 12120  
 gtgtgggggt ggcagaagtc tgccccagca tggctgtcgg ccagcaggag tgcctattcc 12180  
 accctaagca ggccagggac ttggctggag agtagaagcc ctgaagctgc ggggggtcgg 12240  
 ggaagggaag gagtgaagggt tgccaaagac actgaaaaga ctctggtggg gcccaaggcc 12300  
 cagatttggg gtttgggggt cctgagcaag catcccagcc caaacttact gcttgagatt 12360  
 20 tctgttaagt tgtttcagct atgggatcag gaccaggacc cactgggcac ctaagacaat 12420  
 ggcttacatg atgggttttg agaagttcct agaaggcttt ttctgcatcc cctgaagcat 12480  
 cctctccag gtgcccctta aaaacacgta atccctggga ggggtcatgg tgcatacac 12540  
 cgctccttgg ggagaaccca aagatgggag ggcaccttcc ctgtcagaaa gacgagaagg 12600  
 25 gcttgggctc ggaaaagcaa gaagcctcgc aggttccag ggctgggctt gacgagggt 12660  
 cactgggggc ccaggctgccc cctcagctcc accttccctt cctccctccc tgccagagcc 12720  
 aatgaggata ggccccctac cttctcctcc ctcccgggg ctcttagcc aggagtcca 12780  
 tgccaggag gaagtgaag gactccttta ggggtcctt aagacatctc cccatccctg 12840  
 gcctcaaggc ttgggttttg ctggacctac cctcctaact ccagatctct ctggcaccag 12900  
 30 attcccagcc caggggagac acctgagaac ccccagatg gtgacacacc tctgtgttcc 12960  
 tctgtcagg acataacctc ccagcacaga ttgcaaact cctgtctgca ggcacaggca 13020  
 gggctatcgg gcccacggtg tggtccctt gccttgggtc agggagtga gacacagttg 13080  
 cccactgtc cccacccac tgccagacct cttctgccc catgggtcct ggggtggggg 13140  
 agccttggga gtgaagaatg cctctgaccc agattcttca agcagcctct gagctcagag 13200  
 35 gaagagtctg cctcacggca gcctccctgg ggtctagctg tcaatcgccc aggaagaaat 13260  
 acccagcgca ggacccggcg gggagctggc cttctctgtc ttccaggtg cagcagagcg 13320  
 agtgaagga gctgtcttgg gcctgcccag cctggtgccc tgcgggggac tgctggcaca 13380  
 ggactgtgac tgggcttcag ctctgtctga aaatctttgc tcagagcacc tccctagttt 13440  
 40 gatctgatac cccgctgac cctgccagag tccagaggte acggcgccca gccctgcct 13500  
 ccgggaaggt tatccaaat gctccacag ccctgacctt tctgttctt ttgtccctgc 13560  
 agcccaactc ctctttccga ccgcccagca aagacaaccc cccaagcctg gtggccaagg 13620  
 cccagtcctt gccctcggac cagccgggtg ggaccttcag cctctgacc acctcggata 13680  
 ccagcagccc ccagaagtc ctccgacag ccccgccac aggccagctt ccaggccggg 13740  
 45 - ctccccagc gggatcccc cgcacctggc acgcccagat cagcaccagc aacctgtacc 13800  
 tgccccagga cccacgggtt gccaaagggt ccctggctgg tgaggacaca ggtgttgtga 13860  
 cacatgagca gttcaaggct gcgtcagga tgggtgtgga ccagggtgac ccccggtgc 13920  
 tgctggacag ctacgtgaag attggcgagg gctccaccg catcgtctgc ttggcccggt 13980  
 agaagcactc gggccgcccag gtggccgtca agatgatgga cctcaggaag cagcagcgca 14040  
 50 gggagctgct cttcaacgag gtgggaggac aggggtggac acagacgggg gcgttgggga 14100  
 tgggcagtga gcagccagcc aggtggaca tctgtgagca ggggcagtgg gtggccatgc 14160  
 gtctgggcac tgtgctggc actcaggccc ccgctgccc ccagggtgtg atcatgcggg 14220

actaccagca cttcaacgtg gtggagatgt acaagagcta cctgggtgggc gaggagctgt 14280  
 ggggtgctcat ggagttcctg caggaggag ccctcacaga catcgtctcc caagtcaggt 14340  
 gggcagctgg gagggtgga ccctgagtg aggtgccct caccatggcc ctgccagggc 14400  
 5 aatgtggtct tctgcctgtg gccagaaga cttgggatgc ctgggctccc ctgcctgctg 14460  
 gggtaactga gaccaggggg tcttgggagt ggagaagaga aggatagctt ctageccaaag 14520  
 ctcaggcccc agttttcacc agggctatgg cctgactgtg ctgcccaca gattgcctgg 14580  
 gagctgtggg gcctagcacc agggactcct actctgctca gccacccac gacctgccag 14640  
 10 agctaacgtt ctctttcacc ggggtggccc accttctgt ccaggctgaa tgaggagcag 14700  
 attgccactg tgtgtgaggc tgtgtgcag gccctggcct acctgcatgc tcagggtgtc 14760  
 atccaccggg acatcaagag tgaectcacc ctgtgaccc tcgatggcag ggtaggtccc 14820  
 atcctgtccc tggcacagcc acgtccccc tctctctga tccaccactc actccctttt 14880  
 caaccgcagg tgaagctctc ggaecttcgga ttctgtgtc agatcagcaa agacgtccct 14940  
 15 aagaggaagt ccctgggtggg aacccccctac tggatggctc ctgaagtgtat ctccaggtct 15000  
 ttgtatgcca ctgaggtaac cgttccctcc acccccaga cctcccaaaa gcaacttggc 15060  
 aactggcagc tcttctgtgt tggccctcc agtgagctca ccaaaagcag ccctggtttt 15120  
 cagagtccca cctagtcaac accttcccc ctctcgatgg ggctgtctt acccagtgc 15180  
 20 ttgtctgcca ggaacgagtc ctgcaagtgc ttctctcagc tcaagggcag aatggggtat 15240  
 ggccgggccc cctatgtatg atggcctttc tctgagtgc tgacagctgt gtccctatag 15300  
 gcagtggta ctcatgcagg cagtaactgg ccacagggca ggtgaccagg ggaggaagga 15360  
 gacagaccca ccaaggagag ctggggccag ctgtccccc tccaccactg ctgccaccag 15420  
 aacgcagcta ccaatgggccc agggctctggc catggggta gggacatttt cctcctgcag 15480  
 25 gtggatatct ggtctctggg catcatggtg attgagatgg tagatgggga gccaccgtac 15540  
 ttcagtgcct cccagtgca agccatgaag aggtccggg acagccccc acccaagctg 15600  
 aaaaactctc acaaggtcag ttggcacaca aggggtgcgac ctgcagacc ccattcctcc 15660  
 tgaggcaagg ggaccagaac ctgggctccc agcatctccc ttccactgaa gccacagggt 15720  
 ctgggctcct ggaaaaggct cctctttccc cacacaaaac ccgcacctgg gtgtggagcc 15780  
 30 gcactacgc acaagttcgc atgtgcgtc cgacaagtcg cctcccacgg ctgtggcagg 15840  
 agagttgctg cttggcagaa gggttgtgtc ttggcaggca ctggctcgga gccagtggtg 15900  
 gcccatgagc agggaaagcc aggaaccag caatccctgc tgtccaggga gggatccgga 15960  
 gaagcttacc tgagcagaaa ccttctaac ccgtgtcggg agatccatac catgattcga 16020  
 tgtcctgtc catcacggcg agtcggctca tgcctcatcg ttgcacacc cgacacagct 16080  
 35 aagccacagc gtteccctta aagccagtat aagtgcattg aagtgtatac atgtaacct 16140  
 ttttgccaaa tcggcccca ccccgaggc cttactgtg acgcccctg ctggcaggtc 16200  
 agcacggggc tgctaagtgg caccgccatc tgggtggcaa aacaagaaat gtctcagagg 16260  
 gctgaagcct ctctctaaa atagcaaaaa aacaagagt ctgtggcccc aacacaaagc 16320  
 tggatgggag gaccaacagg aaacatcttc caagacaact ggctccttga gcccgaccg 16380  
 40 ctaaccccaa aattagcata taaagatctc cagttggcta attcctcaga ggatgtagcc 16440  
 ttctgcccga gactcagcct catcccaaga tactggctca aaatgaacca agataagccc 16500  
 ttgctttaga ctcttaaggc cttagagcaac aaagaaatct tcttttcag gtctcacttt 16560  
 attttctatt ttccagagta ctctctcacc ctgactgtt ttgtttctgt tgtgttgg 16620  
 45 tttttttttt tttttttttt tggagatgga gtctctctct gttgtcagg ctggaatgca 16680  
 gtggtgcgat ctgagctcac tgcaacctcc gcctcctggg ttcaagcaat tctcctgcct 16740  
 cagcctcctg agtagctggg attacaggca cgtgccacca tgctcaacta atttttgtat 16800  
 ttttagtaga gacagggttt cgccatgttg gtcaggctgg tctacgaact cctgacctcg 16860  
 taatctgccc aacttggcct ccaaaagtgc tgggattaca ggcttgagcc actgcgccc 16920  
 50 gcgacctgtt tttaaaatct caaaagccct atgtggcaga cagggaagc atactttatc 16980  
 actagcccat ttacagatg agaaaactga ggcctagaga aaactgtgac ttgcctgaga 17040  
 tcacggatag agccagatct ggatcactga tgccaatcct ctgcccctc cacagagcta 17100

EP 1 085 093 A2

tagcatctga atgctgagag ccttgagggg gtggggaggg acaaggggaa aggaagttaa 17160  
 aaaaccagcg aattcatgac ttcaaaacaa tgataagtcc aggcaatcag gtcacccccga 17220  
 agtgactgca aattgtggct tcattctact gccctgcctc tacaggtctc cccagtgtctg 17280  
 cgagacttcc tggagcggat gctggtgcgg gacccccaa agagagccac agcccaggag 17340  
 ctcttagacc accccttctt gctgcagaca gggctacctg agtgcctggt gcccctgac 17400  
 cagctctacc gaaagcagac ctccacctgc tgagcccacc ccaagtatgc ctgccacctc 17460  
 cgcccacagg cagggcacac tgggcagcca gcctgccggc aggacttgcc tgccctctcc 17520  
 tctcagtatt ctctccaaag attgaaatgt gaagccccag cccaccctc tgcccttcag 17580  
 cctactgggc caggccggac ctgccccctc agtgtctctc cctcccgagt cccagatgg 17640  
 agaccccttt ctacaggatg accccttgat atttgacag ggatatttct aagaaacgca 17700  
 gaggccagcg ttctggcct ctgcagccaa cacagtagaa aaggctgctg tggtttttta 17760  
 aaggcagttg tccactagtg tcctaggcca ctgcagaggg cagactgctg gtctccacag 17820  
 atacctgctg ttctcagctc cagcttcaaa cctcaggtct cgagagggcc acggggtggt 17880  
 ttttatgacc ggaatccgc ttctccctc acgtctgatg tctgaagggt gcagtccac 17940  
 ctgtacagcc cctccccgcc cagaactgtg aatggcctgc tccaggccat ggctgggggc 18000  
 agggagttag gggacaattt ctgagtgaag gagaaagaat ggggtcgggt gtgaagggtc 18060  
 tctcacttta cagaatggag agaacatcgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt 18120  
 gtgtgtgtaa ggggaggaaa gccacctga cagcccagggt cctccagggt caccacagc 18180  
 cagtttcagg aaggctgccc ctctctccca ctaagtctg gcctgaagggt acctgcttcc 18240  
 ttggcctggc tccacctct cactcctgt gtctacctg ccagtggagt ggtccatgct 18300  
 aagtctaaca ctctgggag ctcaggaggc ttctgagctt ctctgtact gtgcatcgtg 18360  
 agggccagag acaggaatgt aaggattggc aactgtgtta cctttcaagt ttatctcaat 18420  
 aaccagggtca tcagggaccc attgttctct tcagaaccct atctgggaga gaaggcgaac 18480  
 cacctccggg ttccatcat gtcaagggtca caggcatcca tgtgtgcaaa ccatctgccc 18540  
 cagctgcctc cacagactgc tgtctccttg tctcctcgg ccctgcccc cttcagggt 18600  
 gctgtgagat ggaattccag gaaagaactt caggtgtctg gacccttct atctagataa 18660  
 tatttttaga ttcttctgct cctagtgtac ctacctggg gcaaagaaat tgcaaggact 18720  
 ttttttaag ggtcagagtt ttcaaaacaa aagcatcttc ctagaaatt tttgtgaatt 18780  
 gtttgactt gtgcctgtt taaattaaat tgagtgttca aagccattgg gcttctgtg 18840  
 tctctgggag cggagaccgg cgtcttggg ggggggtctc ctgtggcgg tgaatctcgt 18900  
 gtacccctcc ctctcccca cgtgagctct ccagcagcca caccacagaa caccacactt 18960  
 ccctggtggc ctgtggacc gaaaggaggg cagagaggaa gggaaacagg aagtgaagg 19020  
 cccttgggaa tgaaggcg 19038

<210> 12  
 <211> 146  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> CDS  
 <222> (2)..(145)

<400> 12

g cac cgg gat atc aag ggg cag aat gtg ctg ctg aca gag aat gct gag 49  
 His Arg Asp Ile Lys Gly Gln Asn Val Leu Leu Thr Glu Asn Ala Glu  
 1 5 10 15

EP 1.085 093 A2

gtc aag cta gtg gat ttt ggg gtg agt gct cag gtg gac cgc acc gtg 97  
Val Lys Leu Val Asp Phe Gly Val Ser Ala Gln Val Asp Arg Thr Val

20 25 30

ggc aga cgg aac act ttc att ggg act ccc tac tgg atg gcc ccc gag g 146  
Gly Arg Arg Asn Thr Phe Ile Gly Thr Pro Tyr Trp Met Ala Pro Glu

35 40 45

<210> 13

<211> 48

<212> PRT

<213> Homo sapiens

<400> 13

His Arg Asp Ile Lys Gly Gln Asn Val Leu Leu Thr Glu Asn Ala Glu

1 5 10 15

Val Lys Leu Val Asp Phe Gly Val Ser Ala Gln Val Asp Arg Thr Val

20 25 30

Gly Arg Arg Asn Thr Phe Ile Gly Thr Pro Tyr Trp Met Ala Pro Glu

35 40 45

<210> 14

<211> 18

<212> DNA

<213> Homo sapiens

<400> 14

atgcamcang ayathaar

18

<210> 15

<211> 20

<212> DNA

<213> Homo sapiens

<400> 15

gcnacytcng gngccatcca

20

<210> 16

<211> 27

<212> DNA

<213> Homo sapiens

<400> 16

cccgaattca tgcamcanga yathaar

27

<210> 17

<211> 29

<212> DNA

<213> Homo sapiens

<400> 17

cccgaattcg cnacytcngg ngccatcca

29

<210> 18

<211> 17

<212> DNA

<213> Homo sapiens

<400> 18

gagtgactcc atcctgc

17

<210> 19

<211> 17

<212> DNA

<213> Homo sapiens

<400> 19

gtagggggtt cccacca

17

# Claims

1. An isolated polynucleotide molecule comprising a nucleotide sequence encoding an MLK4 gene product from a human; wherein the MLK4 gene product comprises the amino acid sequence of SEQ ID NO:2.
2. The isolated polynucleotide sequence of claim 1 comprising the nucleotide sequence of SEQ ID NO:1.
3. An isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:1.
4. An isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of a polynucleotide molecule comprising a nucleotide sequence encoding an MLK4 gene product from a human, wherein the MLK4 gene product comprises the amino acid sequence of SEQ ID NO:2.
5. The isolated polynucleotide molecule of claim 4, wherein the nucleotide sequence encoding the MLK4 gene product comprises the nucleotide sequence of SEQ ID NO:1.

6. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a PAK4 gene product from a human, wherein the PAK4 gene product comprises the amino acid sequence of SEQ ID NO:4.
7. The isolated polynucleotide sequence of claim 6 comprising the nucleotide sequence of SEQ ID NO:3.
8. An isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:3.
9. An isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of a polynucleotide molecule comprising a nucleotide sequence encoding a PAK4 gene product from a human, wherein the PAK4 gene product comprises the amino acid sequence of SEQ ID NO:4.
10. The isolated polynucleotide molecule of claim 9, wherein the nucleotide sequence encoding the PAK4 gene product comprises the nucleotide sequence of SEQ ID NO:3.
11. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a PAK5 gene product from a human, wherein the PAK5 gene product comprises the amino acid sequence of SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10.
12. The isolated polynucleotide sequence of claim 11, comprising the nucleotide sequence of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 from nt 199 to nt 2244, or SEQ ID NO:11 from nt 6125 to nt 17433.
13. An isolated polynucleotide molecule comprising the nucleotide sequence of an exon of SEQ ID NO:7.
14. An isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 from nt 199 to nt 2244, or SEQ ID NO:11 from nt 6125 to nt 17433.
15. An isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of a polynucleotide molecule comprising a nucleotide sequence encoding a PAK5 gene product from a human, wherein the PAK5 gene product comprises the amino acid sequence of SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10.
16. The isolated polynucleotide molecule of claim 15, wherein the nucleotide sequence encoding the PAK5 gene product comprises the nucleotide sequence of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 from nt 199 to nt 2244, or SEQ ID NO:11 from nt 6125 to nt 17433.
17. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a YSK2 gene product from a human, wherein the YSK2 gene product comprises the amino acid sequence of SEQ ID NO:13.
18. The isolated polynucleotide sequence of claim 17, comprising the nucleotide sequence of SEQ ID NO:12.
19. An isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:12.
20. An isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of a polynucleotide molecule comprising a nucleotide sequence encoding a YSK2 gene product from a human, wherein the YSK2 gene product comprises the amino acid sequence of SEQ ID NO:13.
21. The isolated polynucleotide molecule of claim 20, wherein the nucleotide sequence encoding the YSK2 gene product comprises the nucleotide sequence of SEQ ID NO:12.
22. A recombinant vector comprising any of the polynucleotide molecules of claims 1-21.
23. A transformed host cell comprising the recombinant vector of claim 22.
24. A substantially purified or isolated polypeptide comprising a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:13.

25. A method of preparing a substantially purified or isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:13, comprising culturing host cells of claim 23 under conditions conducive to the expression of the polypeptide or peptide fragment, and recovering in substantially purified or isolated form the polypeptide or peptide fragment from the cell culture.

26. An isolated antibody specific for a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:13.

27. The isolated antibody of claim 26 which is specific for amino acid residues 1-10 of SEQ ID NO:13.

28. A method of screening for compounds that affect the cellular levels of a JNKKK gene product, comprising:

- a) applying a test compound to a cellular test sample;
- b) determining the cellular level of at least one JNKKK gene product in the test sample wherein the gene product is a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:13 or an mRNA encoding a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:13; and
- c) comparing the levels of the gene product in the test sample with that in a reference sample;

wherein a specific change in the cellular levels of the gene product in the test sample as compared to the reference sample indicates that the compound affects the cellular levels of gene product from a JNKKK gene.

29. The method of claim 28, wherein the gene product is an mRNA.

30. The method of claim 28 further comprising the step of applying a stress event to the test sample, and determining the effect of the test compound on the response of the test sample to the stress event.

31. The method of claim 28, wherein the stress event is exposure to ultraviolet radiation.

32. The method of claim 29, wherein the stress event is exposure to an inflammatory cytokine.

33. The method of claim 28, wherein the test and reference samples are cultured cells.

34. The method of claim 28, wherein the test and reference samples are cultured skin tissues.

35. The method of claim 28, wherein the test and reference samples are animals.

36. A method of screening for compounds that affect the activity of a JNKKK, the method comprising:

- a) applying a test compound to a test sample;
- b) determining the activity of a JNKKK in the test sample and a reference sample, wherein the JNKKK comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:13;

wherein a test compound that alters the JNKKK activity in the test sample as compared to the reference sample is identified as a compound that affects the activity of the JNKKK.

37. The method of claim 36, wherein the step of determining the activity of the JNKKK comprises determining kinase activity of the JNKKK.

38. The method of claim 36, further comprising the step of applying a stress event to the test sample and determining the effect of the test compound on the response of the test sample to the stress event.

39. The method of claim 38, wherein the stress event is ultra-violet radiation.

40. The method of claim 38, wherein the stress event is an inflammatory cytokine.

41. The method of claim 36, wherein the test and reference samples are cultured cells.

42. The method of claim 36 wherein the test and reference samples are cultured skin tissues.

43. A method for identifying a compound that binds to a PAK5 polypeptide comprising the amino acid sequence of SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10, or that binds to a YSK2 polypeptide comprising the amino acid sequence of SEQ ID NO:13, comprising:

- a) contacting a test compound with the polypeptide for a time sufficient to form polypeptide/compound complex; and
- b) detecting the complex; so that if a polypeptide/test compound complex is detected, a compound that binds to the PAK5 polypeptide or YSK2 polypeptide is identified.

44. A method of screening for compounds that affect the expression of a gene that encodes a JNKKK gene product, comprising:

- (a) applying a test compound to a test sample;
- (b) determining the expression level of at least one gene in cells of the test sample, wherein the gene encodes a JNKKK gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10 and 13; and
- (c) comparing the expression level of the gene in the test sample with that in a reference sample;


wherein a specific change in the expression of the gene in the test sample as compared to the reference sample indicates that the test compound affects the expression of the gene.

45. The method of claim 44, further comprising the step of applying a stress event to the test sample and determining the effect of the test compound on the gene expression response of the test sample to the stress event.

46. A method of detecting an MLK4-, PAK4-, PAK5- or YSK2-related polynucleotide in a sample, comprising contacting the sample with a compound that binds to and forms a complex with the particular polynucleotide for a period of time sufficient to form the complex, and detecting the complex, so that if a complex is detected, the MLK4, PAK4, PAK5 or YSK2-related polynucleotide, respectively, is detected.

47. The method of claim 46, wherein the method comprises contacting the sample under stringent hybridization conditions with nucleic acid primers that anneal to the particular polynucleotide under such hybridization conditions, and amplifying the annealed polynucleotides, so that if a particular polynucleotide is amplified, the MLK4-, PAK4-, PAK5- or YSK2-related polynucleotide, respectively, is detected.





**FIG. 1**




FIG. 2




FIG. 3B




FIG. 3A

**THIS PAGE BLANK (USPTO)**

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 1 085 093 A3**

(12)

**EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:

**30.10.2002 Bulletin 2002/44**

(43) Date of publication A2:

**21.03.2001 Bulletin 2001/12**

(21) Application number: **00307866.4**

(22) Date of filing: **12.09.2000**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**

Designated Extension States:

**AL LT LV MK RO SI**

(30) Priority: **20.09.1999 US 155029 P**

(71) Applicant: **NEW YORK UNIVERSITY  
New York, NY 10012 (US)**

(72) Inventors:

- **Blumenberg, Miroslav  
New York, New York 10016 (US)**
- **Gazel, Alix M.  
11370, Leucate (FR)**

(74) Representative: **Vossius, Volker, Dr. et al  
Patent- und Rechtsanwaltskanzlei  
Geibelstrasse 6  
81679 München (DE)**

(54) **Genes and polynucleotides associated with ultraviolet radiation-mediated skin damage and uses thereof**

(57) The invention relates to novel polynucleotides and their encoded gene products that are expressed in skin cells, particularly keratinocytes, and methods of using the same. Specifically, the present invention provides polynucleotides encoding several novel protein kinases that are c-Jun N-terminal kinase kinase kinases, i.e., MLK4, PAK4, PAK5 and YSK2. In addition, the in-

vention provides methods of using the disclosed polynucleotides and their gene products in drug discovery, particularly in screening for drugs that can reduce ultraviolet light-induced damage of the skin, inflammation and psoriasis, and drugs that can enhance wound healing.

**EP 1 085 093 A3**



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 00 30 7866

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	TIBBLES, L.A. AND WOODGETT, J.R.: "The stress-activated protein kinase pathways" CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 55, 1999, pages 1230-1254, XP002196334 Basel	3,4	C12N15/54 C12N9/12 C07K16/40 C12Q1/68 C12Q1/48 G01N33/68
Y	* the whole document, in particular: paragraph bridging pages 1232-1233*	1,2,5, 24-26, 28-42, 44-47	
X	US 5 854 043 A (JOHNSON GARY L) 29 December 1998 (1998-12-29)	3,4,22, 23	
Y	* the whole document, in particular column 47-59 and summary)*	1,2,5, 24-26, 28-42, 44-47	
X,D	DIENER K., ET AL.: "Activation of the c-Jun N-terminal kinase pathway by a novel protein kinase related to human germinal center kinase" PROC. NAT. ACAD. SCI. USA, vol. 94, 1997, pages 9687-9692, XP002196509 * the whole document *	3,4	TECHNICAL FIELDS SEARCHED (Int.Cl.7)  C12N C07K
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 24 April 2002	Examiner Krueger, J
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

EPO FORM 1503 (01.02) (P04/001)

European Patent  
Office

Application Number

EP 00 30 7866

**CLAIMS INCURRING FEES**

The present European patent application comprised at the time of filing more than ten claims.

- ☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

**LACK OF UNITY OF INVENTION**

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

- ☐ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- ☒ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:
- 1-5(complete);22-26,28-42,44-47(partial)



European Patent  
Office

**LACK OF UNITY OF INVENTION  
SHEET B**

Application Number

EP 00 30 7866

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

**1. Claims: 1-5 (complete); 22-26, 28-42, 44-47 (partial)**

An isolated polynucleotide encoding a partial MLK4 gene product having the SEQ ID NO 2 from a human, sequences comprising this, homologous sequences and substantial portions thereof. A recombinant vector comprising the MLK4 partial polynucleotide (SEQ ID NO 1), host cells, purified MLK4 polypeptides, antibodies, screening methods for cellular levels and activities, methods for identifying interactors and compounds that influence expression and methods of detecting the MLK4 polynucleotide.

**2. Claims: 6-10 (complete); 22-26, 28-42, 44-47 (partial)**

An isolated polynucleotide encoding a partial PAK4 gene product having the SEQ ID NO 4 from a human, sequences comprising this, homologous sequences and substantial portions thereof. A recombinant vector comprising the partial PAK4 polynucleotide (SEQ ID NO 3), host cells, purified PAK4 polypeptides, antibodies, screening methods for cellular levels and activities, methods for identifying interactors and compounds that influence expression and methods of detecting the PAK4 polynucleotide.

**3. Claims: 11-16 (complete); 22-26, 28-47 (partial)**

An isolated polynucleotide encoding an PAK5 gene product having the SEQ ID NO 6, 8, or 10 from a human, sequences comprising this, homologous sequences and substantial portions thereof. A recombinant vector comprising the PAK5 polynucleotide (SEQ ID NO 5, 7, 9 or 11), host cells, purified PAK5 polypeptides, antibodies, screening methods for cellular levels and activities, methods for identifying interactors and compounds that influence expression and methods of detecting the PAK5 polynucleotide.

**4. Claims: 17-21, 27 (complete); 22-26, 28-47 (partial)**

An isolated polynucleotide encoding a partial YSK2 gene product having the SEQ ID NO 13 from a human, sequences comprising this, homologous sequences and substantial portions thereof. A recombinant vector comprising the YSK2 partial polynucleotide (SEQ ID NO 12), host cells, purified YSK2 polypeptides, antibodies, screening methods for cellular levels and activities, methods for identifying interactors and compounds that influence expression and methods of detecting the YSK2 polynucleotide.



**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 30 7866

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

24-04-2002

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5854043 A	29-12-1998	US 5405941 A	11-04-1995
		US 6074861 A	13-06-2000
		US 5981265 A	09-11-1999
		US 5753446 A	19-05-1998
		US 6333170 B	25-12-2001
		AU 697340 B	01-10-1998
		AU 6666394 A	08-11-1994
		CA 2160548 A	27-10-1994
		EP 0694044 A	31-01-1996
		EP 0755406 A	29-01-1997
		FI 954894 A	13-10-1995
		JP 8509128 T	01-10-1996
		NO 954094 A	13-12-1995
		NZ 266067 A	22-09-1997
		PL 311142 A	05-02-1996
		WO 9424159 A	27-10-1994
		WO 9528421 A	26-10-1995
		AU 703070 B	11-03-1999
		AU 8017794 A	10-11-1995
		CA 2186526 A	26-10-1995
		JP 9511906 T	02-12-1997

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**